NZ611525B2 - Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles - Google Patents
Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles Download PDFInfo
- Publication number
- NZ611525B2 NZ611525B2 NZ611525A NZ61152512A NZ611525B2 NZ 611525 B2 NZ611525 B2 NZ 611525B2 NZ 611525 A NZ611525 A NZ 611525A NZ 61152512 A NZ61152512 A NZ 61152512A NZ 611525 B2 NZ611525 B2 NZ 611525B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- compound
- tubulin
- glu
- use according
- Prior art date
Links
- 230000004044 response Effects 0.000 title claims abstract description 47
- 239000000090 biomarker Substances 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title description 8
- 229940079593 drugs Drugs 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 142
- 210000004027 cells Anatomy 0.000 claims description 125
- 125000000217 alkyl group Chemical group 0.000 claims description 90
- 239000011780 sodium chloride Substances 0.000 claims description 72
- 150000003839 salts Chemical class 0.000 claims description 69
- 125000003545 alkoxy group Chemical group 0.000 claims description 65
- 201000011510 cancer Diseases 0.000 claims description 60
- 150000001408 amides Chemical class 0.000 claims description 45
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 42
- 150000002148 esters Chemical class 0.000 claims description 40
- -1 monoalkylamino Chemical group 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 35
- 235000001014 amino acid Nutrition 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
- 241000282414 Homo sapiens Species 0.000 claims description 29
- 108090001123 antibodies Proteins 0.000 claims description 29
- 102000004965 antibodies Human genes 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 210000001519 tissues Anatomy 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 23
- 125000004076 pyridyl group Chemical group 0.000 claims description 23
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 21
- 150000002431 hydrogen Chemical group 0.000 claims description 21
- 201000001441 melanoma Diseases 0.000 claims description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 19
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 18
- 206010025650 Malignant melanoma Diseases 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 201000005202 lung cancer Diseases 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 239000000651 prodrug Substances 0.000 claims description 18
- 229940002612 prodrugs Drugs 0.000 claims description 18
- 150000001261 hydroxy acids Chemical class 0.000 claims description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 15
- 206010033128 Ovarian cancer Diseases 0.000 claims description 14
- 201000011231 colorectal cancer Diseases 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 10
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 230000000977 initiatory Effects 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 9
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 9
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010017758 Gastric cancer Diseases 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 210000001124 Body Fluids Anatomy 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 201000005216 brain cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 230000000955 neuroendocrine Effects 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims 1
- 102000028664 Microtubules Human genes 0.000 description 47
- 108091022031 Microtubules Proteins 0.000 description 47
- 210000004688 Microtubules Anatomy 0.000 description 47
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 32
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 30
- 229950006344 Nocodazole Drugs 0.000 description 30
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 28
- 229960001592 Paclitaxel Drugs 0.000 description 28
- 229930003347 taxol Natural products 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 25
- 239000000203 mixture Substances 0.000 description 24
- 229960003048 Vinblastine Drugs 0.000 description 23
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 23
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 20
- 238000004166 bioassay Methods 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- 229960001338 colchicine Drugs 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 102000000132 Alpha tubulin Human genes 0.000 description 11
- 108050008484 Alpha tubulin Proteins 0.000 description 11
- 238000003364 immunohistochemistry Methods 0.000 description 11
- 206010059512 Apoptosis Diseases 0.000 description 10
- 206010003816 Autoimmune disease Diseases 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- 102000004243 Tubulin Human genes 0.000 description 9
- 108090000704 Tubulin Proteins 0.000 description 9
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 9
- 230000000394 mitotic Effects 0.000 description 9
- 230000001613 neoplastic Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 229940049906 Glutamate Drugs 0.000 description 8
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 238000002318 immunoblotting Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000001965 increased Effects 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 210000004072 Lung Anatomy 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 229940024606 Amino Acids Drugs 0.000 description 6
- 101710031972 ODA6 Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 210000000056 organs Anatomy 0.000 description 6
- 239000012188 paraffin wax Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 5
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 5
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 102100014001 ABCB1 Human genes 0.000 description 4
- 101710027066 ALB Proteins 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 229950004398 Broxuridine Drugs 0.000 description 4
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 4
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 4
- 229940035295 Ting Drugs 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000011068 load Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Inorganic materials [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 108020005542 tubulin-tyrosine ligase family Proteins 0.000 description 4
- 102000007432 tubulin-tyrosine ligase family Human genes 0.000 description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 108050008483 Beta tubulin Proteins 0.000 description 3
- 102000000131 Beta tubulin Human genes 0.000 description 3
- 210000001185 Bone Marrow Anatomy 0.000 description 3
- 210000000988 Bone and Bones Anatomy 0.000 description 3
- 210000000481 Breast Anatomy 0.000 description 3
- 210000001072 Colon Anatomy 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 210000000664 Rectum Anatomy 0.000 description 3
- 108020004459 Small Interfering RNA Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 239000006143 cell culture media Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001472 cytotoxic Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 108020004707 nucleic acids Chemical class 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 239000002924 silencing RNA Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004083 survival Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- VUGRPJUREUOUIO-UHFFFAOYSA-N 2H-benzotriazol-4-yloxy-tris(dimethylamino)phosphanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)[P+](N(C)C)(N(C)C)OC1=CC=CC2=C1N=NN2 VUGRPJUREUOUIO-UHFFFAOYSA-N 0.000 description 2
- HJFCVJKLGPYQDB-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine Chemical compound C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 HJFCVJKLGPYQDB-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N Adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N Bisbenzimide Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M CHEMBL593252 Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 102000005367 Carboxypeptidases Human genes 0.000 description 2
- 108010006303 Carboxypeptidases Proteins 0.000 description 2
- 210000003679 Cervix Uteri Anatomy 0.000 description 2
- 101710028159 DNTT Proteins 0.000 description 2
- 102100002445 DNTT Human genes 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229940034984 ENDOCRINE THERAPY ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Drugs 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000004851 Immunoglobulin G Human genes 0.000 description 2
- 108090001095 Immunoglobulin G Proteins 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- 102100011339 KLK3 Human genes 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 210000001365 Lymphatic Vessels Anatomy 0.000 description 2
- 206010061232 Lymphoproliferative disease Diseases 0.000 description 2
- 206010027476 Metastasis Diseases 0.000 description 2
- 208000003250 Mixed Connective Tissue Disease Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N Pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N Suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101710033656 TUBA1A Proteins 0.000 description 2
- 102100004216 TUBA1A Human genes 0.000 description 2
- 101710018040 TUBA3C Proteins 0.000 description 2
- 102100018405 TUBA3C Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001541 Thymus Gland Anatomy 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000001028 anti-proliferant Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- LSFOZQQVTWFMNS-UHFFFAOYSA-N avanbulin Chemical compound C1=CC(N)=CC=C1C(=O)CN1C2=CC=CC=C2N=C1C1=NON=C1NCCC#N LSFOZQQVTWFMNS-UHFFFAOYSA-N 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000035572 chemosensitivity Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002596 correlated Effects 0.000 description 2
- 238000003235 crystal violet staining Methods 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009261 endocrine therapy Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229960004275 glycolic acid Drugs 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 150000002829 nitrogen Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- 200000000008 restenosis Diseases 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 238000010518 undesired secondary reaction Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N (2S)-2-acetamido-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (E)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- SJSYJHLLBBSLIH-SDNWHVSQSA-N (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- YBKSULBKIFNMCF-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[2-[4-(3-hydroxypropylamino)-1,2,5-oxadiazol-3-yl]benzimidazol-1-yl]ethanone;3-[[4-[1-[2-(4-chlorophenyl)-2-oxoethyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-yl]amino]propanenitrile Chemical compound OCCCNC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)C1=CC=C(Cl)C=C1.C1=CC(Cl)=CC=C1C(=O)CN1C2=CC=CC=C2N=C1C1=NON=C1NCCC#N YBKSULBKIFNMCF-UHFFFAOYSA-N 0.000 description 1
- FIONSPWWEQBPKZ-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-1-phenylethanone Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)C1=CC=CC=C1 FIONSPWWEQBPKZ-UHFFFAOYSA-N 0.000 description 1
- LBCZOTMMGHGTPH-UHFFFAOYSA-N 2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCO)C=C1 LBCZOTMMGHGTPH-UHFFFAOYSA-N 0.000 description 1
- ULUDPLQFSRBULT-UHFFFAOYSA-N 3-[[4-[1-[(3,4-dimethylphenoxy)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-yl]amino]propanenitrile Chemical compound C1=C(C)C(C)=CC=C1OCN1C2=CC=CC=C2N=C1C1=NON=C1NCCC#N ULUDPLQFSRBULT-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-Aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- HBFNOXGYDVYEAJ-UHFFFAOYSA-N 4-[1-(phenoxymethyl)benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1COC1=CC=CC=C1 HBFNOXGYDVYEAJ-UHFFFAOYSA-N 0.000 description 1
- FRGOWFWLSTYAKH-UHFFFAOYSA-N 4-[1-[(4-fluorophenoxy)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1COC1=CC=C(F)C=C1 FRGOWFWLSTYAKH-UHFFFAOYSA-N 0.000 description 1
- 229940046932 4-aminosalicylic acid Drugs 0.000 description 1
- 102100009045 AGTPBP1 Human genes 0.000 description 1
- 101710025676 ALTA Proteins 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 201000004304 Addison's disease Diseases 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 208000005488 Adnexal and Skin Appendage Neoplasms Diseases 0.000 description 1
- 210000004100 Adrenal Glands Anatomy 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 206010048594 Allergic granulomatous angiitis Diseases 0.000 description 1
- 208000004631 Alopecia Areata Diseases 0.000 description 1
- 208000008524 Alveolar Soft Part Sarcoma Diseases 0.000 description 1
- 208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 description 1
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 1
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-N Armstrong's acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Azelaic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 102100013894 BCL2 Human genes 0.000 description 1
- 108060000885 BCL2 Proteins 0.000 description 1
- 102000036638 BRCA1 Human genes 0.000 description 1
- 108010042977 BRCA1 Protein Proteins 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 208000009137 Behcet Syndrome Diseases 0.000 description 1
- 201000008335 Behcet's disease Diseases 0.000 description 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N Bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 description 1
- 102100015175 CAVIN2 Human genes 0.000 description 1
- 101710010268 CAVIN2 Proteins 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N Citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009887 Colitis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N Cyclamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 206010061811 Demyelinating polyneuropathy Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 101700057458 Drice Proteins 0.000 description 1
- 206010073508 Drug reaction with eosinophilia and systemic symptom Diseases 0.000 description 1
- 208000006922 Drug-Related Side Effects and Adverse Reaction Diseases 0.000 description 1
- 229940022766 EGTA Drugs 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 102000027760 ERBB2 Human genes 0.000 description 1
- 230000035695 Efflux Effects 0.000 description 1
- 210000002889 Endothelial Cells Anatomy 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 210000001508 Eye Anatomy 0.000 description 1
- 208000007842 Fibroepithelial Neoplasms Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 208000007465 Giant Cell Arteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018381 Glomus tumour Diseases 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 description 1
- 206010060980 Granular cell tumour Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 206010019939 Herpes gestationis Diseases 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020718 Hyperplasia Diseases 0.000 description 1
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N Iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-O L-lysinium(1+) Chemical compound [NH3+]CCCC[C@H]([NH3+])C([O-])=O KDXKERNSBIXSRK-YFKPBYRVSA-O 0.000 description 1
- 102100000087 LARP6 Human genes 0.000 description 1
- 101700066207 LARP6 Proteins 0.000 description 1
- 206010023774 Large cell lung cancer Diseases 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N Lauric acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 208000007820 Lichen Sclerosus et Atrophicus Diseases 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- 206010024515 Linear IgA disease Diseases 0.000 description 1
- 210000000088 Lip Anatomy 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 206010025135 Lupus erythematosus Diseases 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 210000004324 Lymphatic System Anatomy 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- 206010027191 Meningioma Diseases 0.000 description 1
- 208000010153 Mesonephroma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 208000000811 Mesothelial Neoplasms Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N Methyl bisulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 102000011279 Multidrug resistance protein 1 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- WIKSGWRDYPATMU-UHFFFAOYSA-N N-[2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-1-(4-bromophenyl)ethylidene]hydroxylamine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=NO)C1=CC=C(Br)C=C1 WIKSGWRDYPATMU-UHFFFAOYSA-N 0.000 description 1
- UZMYPBYAISNZHQ-UHFFFAOYSA-N N-[4-[1-[2-(4-chlorophenyl)-2-oxoethyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-yl]acetamide Chemical compound CC(=O)NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)C1=CC=C(Cl)C=C1 UZMYPBYAISNZHQ-UHFFFAOYSA-N 0.000 description 1
- 210000000282 Nails Anatomy 0.000 description 1
- 210000003739 Neck Anatomy 0.000 description 1
- 208000004235 Neutropenia Diseases 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 210000003300 Oropharynx Anatomy 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 208000007312 Paraganglioma Diseases 0.000 description 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 210000000578 Peripheral Nerves Anatomy 0.000 description 1
- 206010034695 Pernicious anaemia Diseases 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N Phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UNJJBGNPUUVVFQ-ZJUUUORDSA-N Phosphatidylserine Chemical compound CCCC(=O)O[C@H](COC(=O)CC)COP(O)(=O)OC[C@H](N)C(O)=O UNJJBGNPUUVVFQ-ZJUUUORDSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N Phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035228 Plasma cell neoplasms Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000005987 Polymyositis Diseases 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 206010038038 Rectal cancer Diseases 0.000 description 1
- 206010038294 Reiter's syndrome Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 description 1
- 208000005511 Schoenlein-Henoch Purpura Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 208000002669 Sex Cord-Gonadal Stromal Tumors Diseases 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N Sodium molybdate Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N Sodium orthovanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 208000004841 Squamous Cell Neoplasms Diseases 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 101710025660 TUB-1A Proteins 0.000 description 1
- 101710033655 TUBA1B Proteins 0.000 description 1
- 102100004214 TUBA1B Human genes 0.000 description 1
- 101710033654 TUBA1C Proteins 0.000 description 1
- 102100004217 TUBA1C Human genes 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 206010043207 Temporal arteritis Diseases 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 206010043778 Thyroiditis Diseases 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 206010044412 Transitional cell carcinoma Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000006786 Trophoblastic Neoplasm Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- BIABKPAXSLKGLN-UHFFFAOYSA-N [dimethylamino(2H-triazolo[4,5-b]pyridin-7-yloxy)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)C(=[N+](C)C)OC1=CC=NC2=C1N=NN2 BIABKPAXSLKGLN-UHFFFAOYSA-N 0.000 description 1
- CZQGINAUZYECAI-UHFFFAOYSA-N [dimethylamino-(2-oxopyridin-1-yl)oxymethylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CN(C)C(=[N+](C)C)ON1C=CC=CC1=O CZQGINAUZYECAI-UHFFFAOYSA-N 0.000 description 1
- NLWSBEIYMWSFEG-UHFFFAOYSA-O [dimethylamino-[(2-oxo-1H-pyridin-3-yl)oxy]methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CN(C)C(=[N+](C)C)OC1=CC=CNC1=O NLWSBEIYMWSFEG-UHFFFAOYSA-O 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000009789 autophagic cell death Effects 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- YCRYJWJNPWZJSR-UHFFFAOYSA-O butylideneazanium Chemical group [CH2-]CCC=[NH2+] YCRYJWJNPWZJSR-UHFFFAOYSA-O 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000003750 conditioning Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003412 degenerative Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000003066 diffuse scleroderma Diseases 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 238000001861 endoscopic biopsy Methods 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol EtOH Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- FFLYUXVZEPLMCL-UHFFFAOYSA-N ethylchloranuidyl formate Chemical compound CC[Cl-]OC=O FFLYUXVZEPLMCL-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- SIVVHUQWDOGLJN-UHFFFAOYSA-N ethylsulfamic acid Chemical group CCNS(O)(=O)=O SIVVHUQWDOGLJN-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 201000005618 glomus tumor Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 201000005708 granuloma annulare Diseases 0.000 description 1
- 201000011580 granulomatous orchitis Diseases 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- 101500002601 human Epidermal growth factor Proteins 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-O hydron;2H-tetrazole Chemical class C1=NN=[NH+]N1 KJUGUADJHNHALS-UHFFFAOYSA-O 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002055 immunohistochemical Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 201000003088 limited scleroderma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004880 lymph fluids Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cells Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002071 myeloproliferative Effects 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 201000010791 peripheral nerve sheath neoplasm Diseases 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- HLIBNTOXKQCYMV-UHFFFAOYSA-N propylsulfamic acid Chemical compound CCCNS(O)(=O)=O HLIBNTOXKQCYMV-UHFFFAOYSA-N 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 201000002661 spondylitis Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 201000009594 systemic scleroderma Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 201000004420 transitional papilloma Diseases 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 108010008314 tyrosine-tubulin Proteins 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 108010032479 tyrosyltubulin carboxypeptidase Proteins 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N β-glycerophosphoric acid Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Abstract
Disclosed is the use of a glu-tubulin as a biomarker for predicting the response to a compound, wherein the compound is a compound of general formula I, and formula I is as defined in the specification.
Description
Use of glu-tubulin as a biomarker of drug response
The present invention generally relates to use of glu-tubulin as a biomarker
for ting the response of a disease, such as a neoplastic or autoimmune
disease, preferably cancer, to a compound of general formula I, such as 3-(4-{1-[2-
(4-amino-phenyl)oxo-ethyl]-1H-benzoimidazolyl}-furazanylamino)-
propionitrile (BAL27862). In other aspects it relates to s and kits involving the
use of the biomarker. Also described are methods of treatment involving the use of
the biomarker.
Microtubules are one of the components of the cell eleton and are
composed of heterodimers of alpha and beta n. Agents that target microtubules
are among the most effective cytotoxic chemotherapeutic agents having a broad
spectrum of activity. ubule destabilising agents (e.g. the vinca-alkaloids such
as vincristine, vinblastine and vinorelbine) are used for example in the treatment of
several types of hematologic malignancies, such as lymphoblastic leukaemia and
ma, as well as solid s, such as lung cancer. Microtubule stabilising
agents (e.g. the taxanes such as paclitaxel, docetaxel) are used for example in the
ent of solid tumours, ing breast, lung and prostate cancer.
However resistance to these known microtubule targeting agents can occur.
The ance can either be inherent or can be acquired after exposure to these
agents. Such resistance therefore impacts t survival rates, as well as choices
of treatment regimes. Several potential mechanisms of resistance have been
identified, and include defects in the microtubule targets, such as elevated levels of
beta-tubulin subtype III and acquired ons in beta-tubulin subtype I that are
known to reduce taxane binding. Furthermore, defects in other cell proteins have
been suggested to be associated with resistance to certain microtubule targeting
agents, such as overexpression of the efflux pump P-glycoprotein (P-gp pump, also
known as multi-drug resistance protein 1 or MDR1). Such factors may then be used
as biomarkers of resistance to these conventional microtubule targeting agents.
A vely recently ered class of microtubule destabilising agents are
compounds encompassed by the formula given below:
R3 R2 N
R4 N
R5 N N
wherein
R represents phenyl, thienyl or pyridinyl
wherein phenyl is optionally substituted by one or two tuents independently
selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino n the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, y, lower
alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are
methylenedioxy;
and n pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by
hydroxy or lower alkoxy;
R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
R2, R3 and R6 represent hydrogen;
R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R4 and R5 together ent methylenedioxy;
and pharmaceutically acceptable salts f;
or wherein
R represents phenyl or pyridinyl
wherein phenyl is optionally tuted by one or two substituents ndently
selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower , hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the en heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, formyl, cyano, n, and nitro; and wherein two adjacent
substituents are methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents oxygen;
R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
R2, R3 and R6 represent hydrogen;
R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R4 and R5 together represent enedioxy;
and pharmaceutically acceptable salts thereof;
and wherein the prefix lower denotes a radical having up to and including a maximum
of 7, ally up to and including a maximum of 4 carbon atoms.
These compounds are disclosed in WO2004/103994 A1, which is
incorporated by cross-reference herein. These compounds have been shown to
arrest tumour cell proliferation and induce apoptosis.
The synthesis of compounds of a I is described in WO2004/103994
A1, in general on pages 29-35, and specifically on pages 39-55, which are
incorporated herein by cross-reference. They may be prepared as disclosed or by an
analogous method to the processes described therein.
One compound falling within this class, known as BAL27862, and shown in
WO2004/103994 A1 as example 58, and specifically orated by reference
, has the structure and chemical name given below:
N N
N N O
Chemical name:
3-(4-{1-[2-(4-Amino-phenyl)oxo-ethyl]-1H-benzoimidazolyl}-furazanylamino)-
propionitrile.
Or herein as Compound A
Further compounds ified in WO2004/103994 A1 as examples 50 and
79 respectively, and also specifically incorporated by cross-reference herein, have
the structures and chemical names given below:
N N
N N O
Chemical name: 2-[2-(4-Amino-furazanyl)-benzoimidazolyl](4-amino-phenyl)-
ethanone
or herein as Compound B
and
N N
N N O
Chemical name: 3-(4-{1-[2-(6-Amino-pyridinyl)oxo-ethyl]-1H-
benzoimidazolyl}-furazanylamino)-propionitrile
or herein as Compound C.
BAL27862 has activity across a broad panel of experimental, solid tumour
xenograft models. Moreover, activity is retained even against tumour models which
were selected for resistance to conventional microtubule targeting agents (including
the vinca-alkaloid ubule ilisers and the microtubule stabilisers paclitaxel
and lone B). BAL27862 activity is not affected by over-expression of the P-gp
pump in any models tested in vitro, nor in human mammary tumour xenografts.
Additionally, BAL27862 retained its activity despite elevated levels of beta-tubulin
subtype III and mutations in tubulin subtype I.
Hence, BAL27862 activity is not affected by a number of factors that confer
resistance to conventional microtubule targeting agents.
Moreover, it is known that compounds of general formula I have a ent
effect on the phenotype of cells compared to other microtubule targeting agents,
including other microtubule destabilisers. Treatment with a compound of general
formula I induces a consistent microtubule phenotype in tumour cell lines derived
from a variety of , for e lung, cervix and breast, as seen in Figure 1.
Staining the microtubules in these cells with an anti-alpha-tubulin antibody shows
that rather than the mitotic spindle fibres of untreated cells, only dot-like structures
are e in the treated cells. This same effect is also shown using Compounds C
and B in Figures 2A and 2B respectively on the lung cancer cell line A549. It is
however very distinct from that observed with the conventional microtubule ing
agents vinblastine, colchicine, paclitaxel and zole as seen in Figures 3B, 3C,
3D and 4, respectively. The microtubules were stained with an anti-alpha-tubulin
antibody and the cells viewed at a 1000 x magnification (Figures 3, 4). For the cells
treated with BAL27862, multiple ke structures are e, whereas, in stark
st, the other conventional drugs produce filamentous microtubule structures, or
dense microtubule aggregate structures. These differences at the phenotypic level, at
nd doses considered l in terms of antiproliferative effect indicate a
difference in the mode of action at the molecular level.
Furthermore, it is known that BAL27862 elicits a dominant microtubule
phenotype in the presence of the other microtubule targeting agents. Treatment with
vinblastine, colchicine, paclitaxel or nocodazole alone induced the microtubule
phenotypes characteristic of these agents (Figure 5A, 5D, 5G, 6C-6F respectively).
However, combination treatment with BAL27862 for the last 4 hours resulted in
disruption of these phenotypes; despite the ued presence of vinblastine,
colchicine, paclitaxel, or nocodazole (Figure 5B, 5E, 5H, 6G-6J tively). In
contrast, treating first with BAL27862 and subsequently for 4 hours in combination
with vinblastine, cine, paclitaxel, or nocodazole had no impact on generation of
the phenotype consistent with BAL27862 treatment (Figure 5C, 5F, 5I, 6K-6N
respectively).
These data all demonstrate that BAL27862 affects microtubule y in a
different manner than conventional microtubule targeting agents.
Thus, from information about conventional microtubule targeting agents,
predictions cannot be made concerning if, or how, particular genes are involved in
the action of nds of formula I.
An object of the present ion is to identify factors which are associated
with response to compounds of formula I or pharmaceutically acceptable tives
thereof, for example to identify factors associated with resistance to compounds of
general formula I, in ular BAL27862 or pharmaceutically acceptable derivatives
thereof, as defined below; and/or to provide the public with a useful .
It has surprisingly been found that glu-tubulin may be used as a ker of
response to treatment with a nd of general formula I or pharmaceutically
acceptable derivatives thereof, as defined below.
In one preferred embodiment of the invention, relatively high glu-tubulin
levels in a tumour sample are associated with inherent and ed resistance to
BAL27862, as described below.
Tubulin is subjected to a variety of posttranslational modifications, including
detyrosination/tyrosination, acetylation, glutamylation, polyglycylation,
phosphorylation of serine residues and phosphorylation of tyrosine residues, making
it one of the most ed proteins known. Many alpha tubulin genes bed to
date t the presence of a carboxy terminal tyrosine on tubulin. It is currently
thought that once tubulin polymerizes and assembles into microtubules, in some
cases a carboxypeptidase (tubulin carboxypeptidase or tubulin tyrosine
carboxypeptidase, TTCP) acts to remove the C-terminal tyrosine from alpha tubulin
exposing the penultimate glutamate. Another enzyme, tubulin tyrosine ligase (TTL),
can reattach this tyrosine. The exact function of this detyrosination/tyrosination cycle
in the cell has yet to be elucidated.
The form of alpha tubulin which does not have a tyrosine, but rather a
glutamate at its C-terminal is known as glu-tubulin or glu tubulin or detyrosinated
tubulin. The term glu-tubulin shall be used herein to refer to the form of alpha tubulin
with a glutamate as the final amino acid at the inal. The ation glutubulin
, shall also encompass forms wherein other post-translational modifications
may additionally be present. The alpha n which forms the basis for the glu-
n is known to exist in multiple variants, subtypes and isoforms, as well as there
being multiple alpha tubulin genes which give rise to these, and all these shall also
be included in the designation glu-tubulin, with the proviso that a glutamate is the
final amino acid at the C-terminal. Preferably it relates to human variants, subtypes
and isoforms of alpha n, with the o that a glutamate is the final amino acid
at the C-terminal. In a more preferred embodiment, a glutamate, not a tyrosine, is the
final amino acid at the C-terminus of alpha tubulin after post-translational
modification. Subtypes of alpha tubulin include, but are not limited to, tubulin alpha
1A, tubulin alpha 1B, tubulin alpha 1C and tubulin alpha 3C/D. The protein
sequences of these es are accessible via the ing National Center for
Biotechnology Information (NCBI) Reference numbers NP_006000, NP_006073,
NP_116093 and NP_005992, tively. These are also listed in Figures 11-14
(NP_006000.2, NP_006073.2, NP_116093.1, NP_005992.1,) as SEQ ID NO. 1-4,
respectively. Glu-tubulin, as described above, does not have the tyrosine at the final
amino acid at the C-terminus of the sequences presented in SEQ. ID. NO. 1-4.
Accordingly, in one aspect, the invention relates to the use of glu-tubulin as a
biomarker for predicting the se to a compound, wherein the compound is a
R3 R2 N
R4 N
R5 N N
compound of general formula I
wherein
R ents phenyl, thienyl or pyridinyl
wherein phenyl is optionally substituted by one or two tuents independently
ed from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower , lower alkylcarbonyloxy, amino,
monoalkylamino, lamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are
methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by
hydroxy or lower alkoxy;
R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
R2, R3 and R6 represent hydrogen;
R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R4 and R5 together represent methylenedioxy;
and ceutically acceptable salts, solvates, esters and amides of naturally
occurring amino acids, small peptides or pegylated hydroxyl acids, salts of such
esters and amides, and polymorphs thereof;
or wherein
R represents phenyl or pyridinyl
wherein phenyl is ally substituted by one or two substituents independently
ed from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, lamino, lower alkoxycarbonylamino, lower
arbonylamino, substituted amino wherein the two tuents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, y, lower
alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent
substituents are methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents oxygen;
R1 ents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
R2, R3 and R6 represent hydrogen;
R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R4 and R5 together represent methylenedioxy;
and pharmaceutically acceptable salts, solvates, esters and amides of
naturally occurring amino acids, small peptides or pegylated hydroxy acids, salts of
such esters and amides, and polymorphs thereof,
and wherein the prefix lower denotes a l having up to and including a maximum
of 7 carbon atoms and, wherein the response is of a disease in a subject and the
biomarker glu-tubulin is measured ex vivo in a sample or s taken from the
human or animal body.
In another aspect, the invention provides a method for ting in a subject
suffering from a cancer the response of that cancer to a nd of general
formula I or to a pharmaceutically able salt, solvate, ester or amide of a
naturally occurring amino acid, small peptide or pegylated hydroxy acid, or to a salt of
such ester or amide, or to a polymorph thereof, as defined in the first aspect of the
invention, comprising the steps of:
a) measuring ex vivo a level of glu-tubulin in a sample pre-obtained from
tumour tissue or circulating tumour cells of the subject to obtain a value or values
representing this level; and
b) comparing the value or values from step a) to a standard value or set of
standard values from subjects with the same cancer type,
wherein a higher glu-tubulin level in the sample ve to the standard value
or set of standard values is predictive of resistance of the subject's cancer to the
compound of formula (I) or to the pharmaceutically acceptable salt, solvate, ester or
amide of a naturally occurring amino acid, small peptide or ted hydroxy acid,
or salt of such ester or amide, or polymorph thereof.
In another aspect, the invention relates to the use of a compound of l
formula I or of a pharmaceutically acceptable salt, solvate, ester or amide of a
lly occurring amino acid, small peptide or pegylated hydroxy acid, or
rph thereof as defined in the first aspect of the invention, for the preparation of
a pharmaceutical composition for ng a cancer in a subject in need thereof,
wherein the t is selected for treatment with the compound of l formula I
or with the salt, solvate, ester or amide of a naturally occurring amino acid, small
peptide or ted hydroxy acid, salt of such ester or amide, or polymorph thereof
as defined in the first aspect of the invention, if the level of glu-tubulin, measured ex
vivo in a sample taken from the subject, is not higher than a standard value or set of
standard values from subjects with the same tumour histotype or from normal cells,
tissue or body fluid.
In another aspect, the invention provides a kit when used for predicting the
response to a compound of general formula I or a pharmaceutically acceptable salt,
e, ester or amide of a naturally occurring amino acid, small peptide or
pegylated hydroxy acid, salt of such ester or amide, or polymorph thereof, as defined
in the first aspect of the invention, comprising reagents necessary for measuring a
level of bulin in a sample taken from a subject with a cancer, comprising a
compound of the following formula
N N
N N O
or a pharmaceutically acceptable salt thereof and further comprising a
ator module which ses a standard value or set of standard values of a
level of glu-tubulin taken from samples of tumour tissue or circulating tumour cells of
subjects with a cancer of the same histotype to which the level of bulin in the
sample is compared.
Certain statements that appear below are broader than what appears in the
statements of the invention above. These statements are provided in the sts of
providing the reader with a better understanding of the invention and its practice. The
reader is directed to the accompanying claim set which defines the scope of the
invention.
One embodiment relates to use of glu-tubulin as a biomarker for predicting
the response to a compound, wherein the compound is a compound of general
formula I,
R3 R2 N
R4 N
R5 N N
R represents phenyl, thienyl or pyridinyl
wherein phenyl is optionally substituted by one or two tuents ndently
selected from alkyl, halo-lower alkyl, y-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
kylamino, dialkylamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower arbonyl, carboxy, lower
carbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are
methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by
hydroxy or lower alkoxy;
R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
R2, R3 and R6 represent hydrogen;
R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R4 and R5 together represent methylenedioxy;
and pharmaceutically acceptable derivatives thereof,
or wherein
R represents phenyl or pyridinyl
wherein phenyl is optionally substituted by one or two substituents independently
selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, lamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two nt
substituents are methylenedioxy;
and n pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X ents oxygen;
R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or lower
alkyl;
R2, R3 and R6 represent hydrogen;
R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R4 and R5 together represent enedioxy;
and pharmaceutically acceptable derivatives thereof;
and wherein the prefix lower denotes a radical having up to and including a
maximum of 7, especially up to and including a maximum of 4 carbon atoms.
Preferably the response may be of a disease in a subject. Also preferably the
response may be to ent, i.e. to treatment with the compound of general
formula I or pharmaceutically able derivatives thereof.
The biomarker glu-tubulin is measured ex vivo in a sample or samples taken
from the human or animal body, preferably taken from the human body.
In a preferred embodiment, described is the use of glu-tubulin as a
biomarker for predicting the resistance of a e in a subject to a compound of
general formula I or ceutically acceptable derivatives thereof as defined
above.
Preferably the pharmaceutically acceptable derivative is selected from the
group consisting of a salt, solvate, pro-drug, salt of a pro-drug, polymorph and isomer
of a compound of general formula I as defined above. Pro-drugs are preferably ester
and amides of naturally occurring amino acids, small peptides or pegylated hydroxy
acids. More preferably, the pro-drug is an amide formed from an amino group
present within the R group of the compound of general formula I and the carboxy
group of glycine, alanine or .
Particularly preferably the compound is
N N
N N O
or a pharmaceutically able salt thereof, preferably a
hydrochloride salt thereof, most preferably a dihydrochloride salt thereof.
Another ment relates to a method for predicting the se of a
disease in a subject to a compound of general formula I or pharmaceutically
acceptable derivatives thereof as defined above, comprising the steps of:
a) measuring a level of glu-tubulin in a sample pre-obtained from the subject
to obtain a value or values representing this level; and
b) comparing the value or values from step a) to a standard value or set of
standard values.
Further preferably the response which is predicted is resistance.
The measuring of a level or levels of glu-tubulin is performed ex-vivo in a
sample or samples pre-obtained from the t. Pre-obtained refers to the fact that
the sample is obtained before it is subjected to any method involving measuring the
level of the biomarker, and pre-obtained is not to be understood as in relation to
treatment. In a preferred embodiment, a higher level of glu-tubulin in the sample from
the subject relative to the standard value or set of rd values predicts
resistance.
Also preferably, the e is a neoplastic or autoimmune disease. More
preferably the disease is cancer. Especially preferably, the cancer is selected from
the group consisting of breast cancer, prostate cancer, cervical , ovarian
cancer, gastric cancer, colorectal cancer (i.e. including colon cancer and rectal
cancer), pancreatic cancer, liver cancer, brain cancer, neuroendocrine cancer, lung
cancer, kidney cancer, hematological malignancies, melanoma and sarcomas. More
especially preferably the cancer is selected from the group consisting of breast
cancer, cervical cancer, ovarian cancer, colorectal cancer, melanoma and lung
cancer. In an especially preferred embodiment the cancer is selected from the group
consisting of lung , melanoma, n cancer and colorectal cancer. In a
particularly red embodiment, wherein inherent resistance is determined, the
cancer is ed from the group consisting of lung cancer, melanoma or colorectal
cancer. In another particularly preferred embodiment, n ed resistance is
determined, the cancer is lung or ovarian cancer.
Also described is a method of treating a neoplastic or autoimmune disease,
preferably cancer, in a subject in need thereof, sing measuring a level of glutubulin
in a sample from the subject to obtain a value or values representing this
level, and treating the subject with a compound of general formula I or a
pharmaceutically acceptable derivative thereof as defined above, if the level of glu-
tubulin in said sample is not higher than a standard value or set of standard values.
Also described is glu-tubulin for use in the treatment of a neoplastic or
autoimmune disease, preferably cancer, comprising measuring a level of glu-tubulin
in a sample from the subject to obtain a value or values representing this level, and
treating the subject with a compound of general formula I or a pharmaceutically
acceptable derivative thereof as defined above, if the level of glu-tubulin is not higher
than a standard value or set of rd values.
The measuring of a level of glu-tubulin is performed ex-vivo in a sample preobtained
from the subject.
Also described is a method of treating a neoplastic or autoimmune disease,
ably cancer, by first decreasing the level of glu-tubulin in a t that has a
sample with a higher level of glu-tubulin compared to a standard level or set of
standard levels, then treating the subject with a compound of l formula I or a
pharmaceutically acceptable derivative thereof as defined above.
Also described is a kit for predicting the response to a compound of general
formula I or a pharmaceutically acceptable derivative thereof, as defined above,
sing reagents necessary for ing the level of bulin in a sample.
More preferably the kit also comprises a comparator module which ses a
standard value or set of standard values to which the level of bulin in the
sample is compared.
More preferably the kit comprises a nd of general formula I or a
pharmaceutically acceptable derivative thereof as defined above. In an especially
preferred embodiment the kit comprises a compound of the following formula or a
pharmaceutically acceptable salt thereof
N N
N N O
Chemical name: S-2,6-Diamino-hexanoic acid [4-(2-{2-[4-(2-cyanoethylamino
)-furazanyl]-benzoimidazolyl}-acetyl)-phenyl]-amide
In a particularly preferred embodiment the pharmaceutically acceptable salt
is a ochloride salt.
Also described is a device for predicting the response to a nd of
l formula I or a pharmaceutically acceptable derivative thereof as defined
above, comprising reagents necessary for measuring a level of glu-tubulin in a
sample and a comparator module which comprises a standard value or set of
standard values to which the level of glu-tubulin in the sample is compared.
In a preferred embodiment, the reagents in the kit or device comprise a
capture reagent comprising a detector for glu-tubulin, and a detector reagent.
Especially preferably the capture t is an dy. Also preferably, the disease
is predicted to be ant to treatment with said compound when glu-tubulin is
higher relative to a standard value or set of standard . In a preferred
embodiment, the comparator module is included in instructions for use of the kit. In
another preferred embodiment the comparator module is in the form of a display
device.
Embodiments of the present invention will now be described by way of
example with reference to the accompanying figures. The invention however is not to
be understood as limited to these embodiments.
Brief Description of the Figures
Figure 1: Shows the treatment of human tumour cell lines from different
ypes with 50 nM BAL27862. The microtubules of mitotic or G2/M arrested cells
were stained after 24 hours ent with 50 nM BAL27862 or vehicle control.
Fig. 1A and 1B: A549 NSCLC cells;
Fig. 1C and 1D: HeLa al cancer cells;
Fig. 1E and 1F: SKBR3 breast cancer cells
Vehicle control treatment: Figures 1A, 1C & 1E,
BAL27862 ent: Figures 1B, 1D & 1F.
Figure 2: Shows the treatment of A549 NSCLC cells with the Compounds B
and C. The microtubules of mitotic or G2/M arrested A549 NSCLC cells were stained
after 24 hours treatment with 80 nM or 20 nM of Compounds B and C, respectively.
The white scale bar represents 10 micrometres.
Fig. 2A: treatment with 20 nM Compound C
Fig. 2B: treatment with 80 nM Compound B
Figure 3: Shows a comparison of treatment of cells with BAL27862
compared to conventional microtubule targeting agents. Microtubules of c or
G2/M arrested A549 NSCLC cells were stained after 24 hours of treatment with 50
nM of A: 62; B: vinblastine; C: colchicine; D: paclitaxel. Stacks of images
taken every 1 µm were processed by using ImageJ software.
Figure 4: Shows a ison of treatment of A549 NSCLC cells with
BAL27862 compared to nocodazole. Microtubules of mitotic or G2/M arrested cells
were stained after 24 h of treatment with various concentrations of nocodazole (B, C
& D) and BAL27862 (E, F & G). A: control, B: Nocodazole 50 nM, C: Nocodazole
100 nM, D: Nocodazole 200 nM, E: BAL27862 20 nM; F: 62 30 nM and G:
BAL27862 50 nM. The white scale bar represents 10 micrometres. Representative
images of the microtubule phenotypes observed are shown.
Figure 5: Shows a combination of treatment with 62 and
conventional microtubule-targeting agents. Microtubules of mitotic or G2/M arrested
A549 NSCLC cells were stained after treatment for the times indicated below. 50 nM
BAL27862, 50 nM vinblastine, 50 nM colchicine and 25 nM paclitaxel were used. The
white scale bar ents 10 micrometres.
Fig. 5A: 24 hours stine treatment;
Fig. 5B: 24 hours vinblastine treatment with the final 4 hours including
BAL27862;
Fig. 5C: 24 hours BAL27862 treatment with the final 4 hours including
stine.
Fig. 5D: 24 hours colchicine treatment;
Fig. 5E: 24 hours colchicine treatment with the final 4 hours including
BAL27862;
Fig. 5F: 24 hours BAL27862 ent with the final 4 hours including
colchicine.
Fig. 5G: 24 hours paclitaxel treatment;
Fig. 5H: 24 hours paclitaxel treatment with the final 4 hours including
BAL27862;
Fig. 5I: 24 hours BAL27862 treatment with the final 4 hours including
paclitaxel.
Figure 6: Shows a combination of treatment with BAL27862 and
nocodazole. Microtubules of mitotic or G2/M ed A549 NSCLC cells were
stained after treatment for the times ted below. 25 nM BAL27862 and
nocodazole at the concentrations indicated below were used. The white scale bar
represents 10 micrometers.
Fig. 6A: 24 hours control treatment;
Fig. 6B: 24 hours of 25 nM BAL27862 treatment;
Fig. 6C: 24 hours of 50 nM nocodazole treatment
Fig. 6D: 24 hours of 100 nM nocodazole treatment
Fig. 6E: 24 hours of 150 nM nocodazole treatment
Fig. 6F: 24 hours of 200 nM nocodazole treatment
Fig. 6G: 24 hours of 50 nM nocodazole treatment with the final 4 hours
including 25 nM BAL27862;
Fig. 6H: 24 hours of 100 nM nocodazole treatment with the final 4 hours
including 25 nM 62;
Fig. 6I: 24 hours of 150 nM nocodazole treatment with the final 4 hours
including 25 nM BAL27862;
Fig. 6J: 24 hours of 200 nM nocodazole treatment with the final 4 hours
including 25 nM BAL27862;
Fig. 6K: 24 hours of 25 nM BAL27862 treatment with the final 4 hours
including 50 nM nocodazole;
Fig. 6L: 24 hours of 25 nM BAL27862 treatment with the final 4 hours
including 100 nM nocodazole;
Fig. 6M: 24 hours of 25 nM BAL27862 treatment with the final 4 hours
including 150 nM nocodazole;
Fig. 6N: 24 hours of 25 nM BAL27862 treatment with the final 4 hours
ing 200 nM nocodazole.
Figure 7: Shows protein ts prepared from patient-derived colorectal
cancer (Fig. 7A), lung cancer (Fig. 7B) and melanoma (Fig. 7C) tumours obtained
from subcutaneous xenografted mice, and analysed by immunoblotting for glu-tubulin
expression, with actin included as a loading control. Three independent s
were analysed in each case (1 – 3). 62, paclitaxel and vinblastine resistance
and sensitivity is as defined in Table 1.
Figure 8: Shows by immunohistochemistry that glu-tubulin levels in tumour
cells are increased in a patient-derived xenografted colorectal tumour defined as
BAL27862 resistant by ex vivo colony outgrowth analysis. Patient-derived tumour
afts (maintained in nude mice) were prepared, fixed and stained for glu-tubulin
protein sion using immunohistochemistry. BAL27862, paclitaxel and
vinblastine resistance and sensitivity is defined in Table 1.
Figure 9: Shows tumour cell lines which were ed for resistance to
BAL27862 through in vitro cultivation in the presence of the compound. Based on
IC 50 determinations, BAL27862 resistance factors versus parental lines were: A549
(3.0 fold); SKOV3 (7.6 fold – resistant 1 line); H460 (5.3 fold) (see Table 2). Whole
cell protein extracts were prepared from parental and resistant lines and analysed by
immunoblotting for glu-tubulin sion. Actin levels were included as a loading
control.
Figure 10: Shows that increased glu-tubulin protein levels are ined in
SKOV3 tumour lines during resistance development. SKOV3 tumour cell lines were
selected for resistance to BAL27862 through in vitro cultivation in the presence of
BAL27862 for increasing time periods. Based on IC50 determinations, BAL27862
resistance factors versus parental lines were: SKOV3 resistant 1 (7.6 fold), SKOV3
resistant 2 (11.6 fold) (see Table 2). Whole cell n extracts were prepared from
parental and resistant lines and analysed by immunoblot for glu-tubulin expression.
Actin levels act as a loading control.
Figure 11: Shows the protein sequence of tubulin alpha-1A chain [Homo
sapiens] (SEQ. ID. No. 1)
Figure 12: Shows the protein ce of n alpha-1B chain [Homo
sapiens] (SEQ ID No. 2)
Figure 13: Shows the protein sequence of n alpha-1C chain [Homo
sapiens] (SEQ. ID. NO. 3)
Figure 14: Shows the protein sequence of Tubulin alpha-3C/D chain [Homo
sapiens] (SEQ. ID. NO. 4)
Detailed Description
Compounds of formula I
The compounds useful in the invention are represented by general formula I:
R3 R2 N
R4 N
R5 N N
n
R represents phenyl, l or pyridinyl
wherein phenyl is optionally substituted by one or two substituents independently
selected from alkyl, ower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, y-lower alkoxy, lower
alkoxy-lower alkoxy, -lower alkoxy, lower alkylcarbonyloxy, amino,
kylamino, lamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are
methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by
hydroxy or lower alkoxy;
R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower
alkyl;
R2, R3 and R6 represent hydrogen;
R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R4 and R5 together represent methylenedioxy;
and pharmaceutically acceptable derivatives thereof,
or wherein
R ents phenyl or pyridinyl
wherein phenyl is optionally substituted by one or two substituents ndently
selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower -lower alkyl,
acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower
alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino,
monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower
alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form
together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower
alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent
substituents are methylenedioxy;
and wherein pyridinyl is optionally substituted by lower alkoxy, amino or halogen;
X represents oxygen;
R1 represents hydrogen, lower alkylcarbonyl, y-lower alkyl or cyano-lower
alkyl;
R2, R3 and R6 represent hydrogen;
R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower
alkoxy;
or R4 and R5 together represent methylenedioxy;
and pharmaceutically able derivatives thereof;
and n the prefix lower s a radical having up to and including a maximum
of 7, especially up to and including a maximum of 4 carbon atoms.
cyclyl designates preferably a saturated, partially saturated or
unsaturated, mono- or bicyclic ring containing 4-10 atoms comprising one, two or
three heteroatoms selected from en, oxygen and sulfur, which may, unless
otherwise specified, be carbon or nitrogen linked, wherein a ring nitrogen atom may
optionally be substituted by a group selected from lower alkyl, amino-lower alkyl, aryl,
aryl-lower alkyl and acyl, and a ring carbon atom may be substituted by lower alkyl,
amino-lower alkyl, aryl, ower alkyl, heteroaryl, lower alkoxy, hydroxy or oxo.
Examples of heterocyclyl are pyrrolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl,
linyl, piperazinyl, dioxolanyl and tetrahydropyranyl.
Acyl designates, for example, arbonyl, cyclohexylcarbonyl,
arylcarbonyl, aryl-lower alkylcarbonyl, or heteroarylcarbonyl. Lower acyl is preferably
lower alkylcarbonyl, in particular propionyl or acetyl.
Preferably, the compound of general formula I is defined as wherein R1 is
ed from the group consisting of hydrogen, acetyl, CH2CH 2CN and
CH 2CH 2CH 2OH.
In one preferred embodiment, the nd of general formula I is selected
from the group consisting of:
4-(1-Phenacyl-1H-benzimidazolyl)-furazanylamine,
4-[1-(4-Bromophenacyl)-1H-benzimidazolyl]-furazanylamine oxime,
N-{4-[1-(4-Chlorophenacyl)-1H-benzimidazolyl]-furazanyl}-acetamide,
4-[1-(4-Chlorophenacyl)-1H-benzimidazolyl]-furazanyl-N-(2-cyanoethyl)-amine
4-[1-(4-Chlorophenacyl)-1H-benzimidazolyl]-furazanyl-N-(3-hydroxypropyl)-
amine,
4-[1-(3-Aminochlorophenacyl)-1H-benzimidazolyl]-furazanylamine
4-[1-(3-Methoxymethoxymethoxy-phenacyl)-1H-benzimidazolyl]-furazan
e,
and ceutically acceptable derivatives thereof.
In another preferred embodiment, the compound of general formula I is
selected from the group consisting of:
N N
wherein
R, Y and R1 are d as follows :
R Y R1
O H
NOH H
NOMe H
O H
NOH H
NOH H
NOMe H
O H
NOH H
NOMe H
O H
NOH H
NOMe H
O H
NOMe H
O H
Cl Cl
O H
NOH H
NOMe H
O H
NOH H
NOMe H
NOMe H
O H
Et N
O Ac
O H
O H
O H
O CN
O CH2CH2CN
O H
O H
O CH2OH
O H
O CH2CH2CN
O H
O CH2CH2CN
O CH2CH2CN
O CH2CH2CN
O H
AcNH
O H
O H
AcHN
O H
O H
O H
O H
O CN
O H
O H
O H
O H
O H
O H
O H
O H
O H
NH N
O CH2CH2CN
NH N
O H
O O O H
O O
O CH2CH2CN
MeO N
or pharmaceutically acceptable tives thereof.
In yet another preferred embodiment, the compound of general formula I is
selected from the group consisting of:
4-(1-Phenoxymethyl-1H-benzimidazolyl)-furazanylamine,
4-[1-(4-Fluorophenoxymethyl)-1H-benzimidazolyl]-furazanylamine,
4-[1-(3,4-Dimethylphenoxymethyl)-1H-benzimidazolyl]-furazanyl-N-(2-
cyanoethyl)-amine
and compounds ented by the formula:
N N
N N O
wherein R and R1 are as defined below
R R1
CH2CH2CN
CH2CH2CN
CH2CH2CN
CH2CH2CH2OH
Cl N
NH N
and pharmaceutically able derivatives thereof.
In still yet another preferred ment the compound of general formula I
R4 N N
R5 N N
wherein R, R4 and R5 are as defined below
R R4 R5
Me Me
Me Me
Me Me
Me Me
Me Me
OMe OMe
OMe OMe
OMe OMe
OMe OMe
OMe OMe
or pharmaceutically acceptable derivatives f.
More preferably, the compound is a compound of general formula I
R3 R2 N
R4 N
R5 N N
wherein
R represents phenyl or pyridinyl
wherein phenyl is optionally substituted by one or two substituents independently
ed from lower alkyl, lower alkoxy, amino, acetylamino, halogen and nitro;
and wherein pyridinyl is optionally substituted by amino or halogen;
X represents a group C=O;
R1 represents hydrogen or cyano-lower alkyl;
R2, R3, R4, R5 and R6 represent hydrogen;
and pharmaceutically acceptable tives thereof,
and wherein the prefix lower s a radical having up to and including a maximum
of 7, especially up to and including a maximum of 4 carbon atoms.
Especially preferably, the compound is represented by the following formula
N N
wherein R, Y and R1 are defined as follows :
R Y R1
O H
O CH2CH2CN
O H
NH N
O CH2CH2CN
NH N
or pharmaceutically acceptable tives thereof.
More especially preferably, the compound is represented by the following
formula
N N
wherein R, Y and R1 are defined as follows:
R Y R1
O CH2CH2CN
O H
O CH2CH2CN
NH N
or pharmaceutically acceptable derivatives thereof.
Particularly preferably, the compound is
N N
N N O
or pharmaceutically acceptable derivatives thereof.
The term tive or derivatives in the phrase “pharmaceutically
acceptable derivative” or “pharmaceutically acceptable derivatives” of compounds of
general formula I relates to salts, es and xes f and to solvates
and complexes of salts thereof, as well as to pro-drugs, polymorphs, and isomers
thereof (including l, geometric and tautomeric isomers) and also salts of prodrugs
thereof. In a more preferred embodiment, it relates to salts and pro-drugs, as
well as to salts of pro-drugs thereof.
Salts are preferably acid addition salts. Salts are formed, preferably with
organic or inorganic acids, from compounds of formula (I) with a basic nitrogen atom,
especially the pharmaceutically able salts. Suitable inorganic acids are, for
example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic
acids, for example acetic acid, nic acid, octanoic acid, decanoic acid,
dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid,
pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino
acids, such as glutamic acid or ic acid, maleic acid, hydroxymaleic acid,
methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic
acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic
acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid,
ethane-1,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1,5-
naphthalene-disulfonic acid, 2-, 3- or ylbenzenesulfonic acid, methylsulfuric
acid, ethylsulfuric acid, dodecylsulfuric acid, N-cyclohexylsulfamic acid, N-methyl-, N-
ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic
acid.
The compound useful in the invention may be administered in the form of a
ug which is broken down in the human or animal body to give a compound of
the formula I. es of ugs include in vivo hydrolysable esters and amides
of a compound of the formula I. Particular ugs considered are ester and amides
of naturally ing amino acids and ester or amides of small peptides, in particular
small peptides consisting of up to five, preferably two or three amino acids as well as
esters and amides of pegylated hydroxy acids, preferably hydroxy acetic acid and
lactic acid. Pro-drug esters are formed from the acid function of the amino acid or the
C terminal of the e and le hydroxy group(s) in the compound of formula I.
Pro-drug amides are formed from the amino function of the amino acid or the N
terminal of the peptide and suitable carboxy group(s) in the compound of formula I, or
from the acid function of the amino acid or the C terminal of the peptide and suitable
amino group(s) in the compound of a I. Particularly preferably the pro-drug
amides are formed from the amino group(s) present within the R group of formula I.
More preferably, the pro-drug is formed by the addition of glycine, alanine or
lysine to the compound of formula I.
Even more ably the compound of general formula I is in the form of a
pro-drug selected from the compounds of formulae:
N N
NH N
N N N O
N N N
N N O
N N O O
O O
O H
N O
N NH2
H H
NH2 NH2 H2N
, , ,
N N
NH N
N O
N N N N
N N O
N N O O
O O
N N
O H
N O
N NH2
H H
NH2 NH2 H2N
, , ,
H2N N
N N N N N O
N N O
N N O O
O O
O H
N O
N NH
H H
NH2 NH H2N
, 2 and .
In an especially preferred ment the compound of general formula I is
in the form of a pro-drug which has the ing formula
N N
N N O
In a most especially preferred embodiment the compound is a
pharmaceutically acceptable salt, preferably a hydrochloride salt, most preferably a
dihydrochloride salt, of a compound of the following formula
N N
N N O
The pharmaceutically active metabolite in vivo in this case is BAL27862.
These pro-drugs may be prepared by processes that are known per se, in
ular, a process, wherein a nd of formula (II)
N N
N N O
(II)
wherein R1 is defined as for formula (I) and Z is CH or N, or a derivative of such a
compound comprising functional groups in protected form,
or a salt thereof is
(1) acylated with an amino acid of formula (III)
R11 (III)
wherein
R10 is selected from en (Gly); methyl (Ala) and protected aminobutyl (Lys) and
R11 is a suitable amino protecting group, and
(2) any protecting groups in a protected derivative of the ing compound are
removed to yield a pro-drug as shown above, and, if so desired,
(3) said pro-drug is converted into a salt by treatment with an acid, or a salt of a
compound of formula (II) is converted into the ponding free compound of
formula (II) or into another salt, and/or a mixture of isomeric product compounds is
separated into the individual isomers.
Acylation of a compound of formula (II) with an amino acid of formula (III) is
performed in a manner known per se, usually in the presence of a suitable polar or
dipolar aprotic solvent, with cooling or heating as required, for example in a
temperature range from imately minus 80°C to approximately plus 150°C,
more preferably from minus 30°C to plus 120°C, especially in a range from
approximately around 0°C to the reflux temperature of the used solvent. ally a
suitable base is added, in particularly an aromatic base like ne or collidine or a
tertiary amine base such as triethylamine or diisopropylethylamine, or an inorganic
basic salt, e.g. potassium or sodium ate.
Acylation may be accomplished under conditions used for amide formation
known per se in peptide chemistry, e.g. with activating agents for the carboxy group,
such as carbodiimides like N,N’-diethyl-, N,N’-dipropyl-, N,N’-diisopropyl-, N,N’-
dicyclohexylcarbodiimide and N-(3-dimethylaminoisopropyl)-N’-ethylcarbodiimidehydrochloride
(EDC), or with agents such as 1-hydroxybenzotriazole (HOBt),
benzotriazolyloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOP),
O-(7-aza-benzotriazolyl)-N,N,N’,N’-tetramethyl-uronium hexafluorophosphate
(HATU), 2-(2-oxo(2H)-pyridyl)-1,1,3,3-tetramethyluronium tetrafluoroborate
(TPTU), optionally in the presence of suitable bases, sts or co-reagents. The
carboxy group may also be ted as acyl halogenide, preferably as acyl chloride,
e.g. by on with thionylchloride or chloride, or as symmetrical or
unsymmetrical anhydride, e.g. by reaction with halogeno formates like ethyl
chloroformate, optionally in the presence of suitable bases, catalysts or co-reagents.
If one or more other functional groups, for example carboxy, hydroxy or
amino, are or need to be protected in a compound of formula (II) or (III), because
they should not take part in the reaction, these are such protecting groups as are
usually applied in the sis of amides like, in particular peptide compounds,
cephalosporins, penicillins, nucleic acid derivatives and sugars, which are known to
the skilled persons. Suitable protecting groups for amino groups are for example tbutyl
ate, benzyl carbamate or 9-fluorenylmethyl ate.
The protecting groups may already be present in precursors and should
protect the functional groups concerned against unwanted secondary reactions, such
as alkylations, acylations, etherifications, esterifications, ions, solvolysis, and
similar reactions. It is a characteristic of protecting groups that they lend themselves
readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis,
reduction, photolysis or also by enzyme activity, for example under conditions
analogous to logical conditions, and that they are not t in the end
products. The specialist knows, or can easily ish, which protecting groups are
suitable with the reactions mentioned hereinabove and hereinafter.
The protection of such functional groups by such protecting groups, the
ting groups themselves, and their removal ons are described for example
in standard reference books for peptide synthesis and in special books on protective
groups such as
J. F. W. McOmie, ctive Groups in Organic Chemistry", Plenum Press, London
and New York 1973, in "Methoden der organischen Chemie" (Methods of organic
chemistry), Houben-Weyl, 4th edition, Volume 15/I, Georg Thieme , Stuttgart
1974, and in T. W. Greene, G. M. Wuts "Protective Groups in Organic Synthesis",
Wiley, New York, 2006.
Disease
The compounds of general formula I have been shown to arrest cell
proliferation and induce cell death, for e by apoptosis.
Dysregulation of cell proliferation, or lack of appropriate cell death, has wide
ranging al implications. A number of diseases associated with such
dysregulation involve hyperproliferation, inflammation, tissue remodeling and repair.
Familiar indications in this category include cancers, restenosis, neointimal
hyperplasia, angiogenesis, endometriosis, lymphoproliferative disorders,
transplantation d pathologies (graft rejection), polyposis, loss of neural function
in the case of tissue remodeling and the like.
Cancer is associated with abnormal cell eration and cell death rates. As
apoptosis is inhibited or delayed in most types of proliferative, neoplastic diseases,
induction of apoptosis is an option for treatment of cancer, especially in cancer types
which show resistance to classic chemotherapy, radiation and immunotherapy
(Apoptosis and Cancer Chemotherapy, Hickman and Dive, eds., Blackwell
Publishing, 1999). Also in autoimmune and transplantation related diseases and
ogies compounds inducing apoptosis may be used to restore normal cell death
processes and therefore can eradicate the symptoms and might cure the es.
Further applications of compounds inducing apoptosis may be in restenosis, i.e.
accumulation of vascular smooth muscle cells in the walls of arteries, and in
persistent infections caused by a failure to eradicate ia- and virus-infected
cells. Furthermore, apoptosis can be induced or reestablished in epithelial cells, in
endothelial cells, in muscle cells, and in others which have lost contact with
extracellular matrix.
A compound according to general formula I or pharmaceutically able
derivatives thereof may be used for the lactic or ally therapeutic
treatment of the human or animal body, in particular for ng a stic disease,
autoimmune disease, lantation related pathology and/or degenerative e.
Examples of such neoplastic diseases include, but are not d to, epithelial
neoplasms, squamous cell neoplasms, basal cell neoplasms, transitional cell
papillomas and carcinomas, adenomas und adenocarcinomas, adnexal and skin
appendage neoplasms, mucoepidermoid neoplasms, cystic neoplasms, mucinous
and serous neoplasms, ducal-, lobular and medullary neoplasms, acinar cell
sms, complex epithelial neoplasms, specialized gonadal neoplasms,
paragangliomas and glomus tumours, naevi and melanomas, soft tissue tumours and
sarcomas, fibromatous neoplasms, myxomatous neoplasms, lipomatous neoplasms,
myomatous sms, complex mixed and stromal neoplasms, fibroepithelial
neoplasms, synovial like neoplasms, mesothelial neoplasms, germ cell neoplasms,
trophoblastic neoplasms, mesonephromas, blood vessel tumours, lymphatic vessel
s, osseous and chondromatous neoplasms, giant cell tumours, laneous
bone tumours, odontogenic tumours, gliomas, neuroepitheliomatous neoplasms,
meningiomas, nerve sheath tumours, granular cell tumours and alveolar soft part
sarcomas, Hodgkin's and non-Hodgkin's lymphomas, other lymphoreticular
neoplasms, plasma cell tumours, mast cell tumours, proliferative diseases,
leukemias, miscellaneous myeloproliferative ers, lymphoproliferative disorders
and myelodysplastic syndromes.
The compounds of general a I or pharmaceutically acceptable
derivatives thereof may be used to treat autoimmune diseases. Examples of such
autoimmune diseases include, but are not limited to, systemic, discoid or subacute
cutaneous lupus matosus, rheumatoid arthritis, antiphospholipid syndrome,
CREST, progressive systemic sclerosis, mixed connective tissue disease (Sharp
syndrome), Reiter's syndrome, juvenile arthritis, cold agglutinin disease, essential
mixed cryoglobulinemia, tic fever, sing spondylitis, chronic polyarthritis,
myasthenia , multiple sclerosis, chronic inflammatory demyelinating
polyneuropathy, Guillan-Barre syndrome, dermatomyositis/ polymyositis,
autoimmune hemolytic anemia, thrompocytopenic purpura, neutropenia, type I
diabetes mellitus, thyroiditis (including Hashimoto's and Grave'disease), Addison's
disease, andular syndrome, pemphigus (vulgaris, foliaceus, sebaceous and
vegetans), bullous and cicatricial pemphigoid, pemphigoid gestationis, epidermolysis
bullosa acquisita, linear IgA disease, lichen sclerosus et atrophicus, morbus Duhring,
psoriasis is, guttate, generalized ar and localized pustular psoriasis,
vitiligo, alopecia areata, primary biliary cirrhosis, autoimmune hepatitis, all forms of
glomerulonephritis, pulmonal hemorrhage (goodpasture syndrome), IgA
pathy, pernicious anemia and mune gastritis, inflammatory bowel
diseases (including colitis ulcerosa and morbus Crohn), Behcet's disease, Celic-
Sprue disease, mune s, mune myocarditis, granulomatous
orchitis, aspermatogenesis without orchitis, idiopatic and secondary pulmonary
fibrosis, inflammatory diseases with a possibility of mune pathogensesis, such
as pyoderma gangrensosum, lichen ruber, sarcoidosis (including Lofgren and
cutaneous/subcutaneous type), granuloma anulare, allergic type I and type IV
immunolgical reaction, asthma bronchiale, pollinosis, atopic, contact and airborne
dermatitis, large vessel itis (giant cell and Takayasu's arteritis), medium sized
vessel vasculitis (polyarteritis nodosa, ki disease), small vessel vasculitis
(Wegener's granulomatosis, Churg Strauss syndrome, microscopic polangiitis,
HenochSchoenlein purpura, essential cryoglobulinemic vasculitis, cutaneous
leukoklastic angiitis), hypersensitivity syndromes, toxic epidermal necrolysis
(Stevens-Johnson syndrome, erythema multiforme), es due to drug side
effects, all forms of cutaneous, organ- specific and systemic effects due to type l-vu
(Coombs fication) immunologic forms of reaction, transplantation related
pathologies, such as acute and chronic graft versus host and host versus graft
disease, involving all organs (skin, heart, kidney, bone marrow, eye, liver, spleen,
lung, muscle, central and peripheral nerve system, connective tissue, bone, blood
and lymphatic vessel, genito-urinary system, ear, cartillage, primary and secondary
lymphatic system including bone marrow, lymph node, thymus, gastrointestinal tract,
including oro-pharynx, esophageus, stomach, small intestine, colon, and rectum,
including parts of above mentioned organs down to single cell level and
substructures, e. g. stem cells).
Particularly preferably, the disease is a neoplastic or autoimmune disease.
In an especially preferred embodiment the e is cancer.
Examples of cancers in terms of the organs and parts of the body affected
include, but are not limited to, the breast, cervix, ovaries, colon, rectum, (including
colon and rectum i.e. colorectal cancer), lung, ding small cell lung cancer, non-
small cell lung cancer, large cell lung cancer and mesothelioma), bone, endocrine
system, adrenal gland, thymus, liver, stomach, intestine, (including gastric cancer),
pancreas, bone marrow, hematological ancies, (such as lymphoma, leukemia,
myeloma or lymphoid ancies), bladder, urinary tract, s, skin, thyroid,
brain, head, neck, te and testis. ably the cancer is ed from the
group consisting of breast cancer, prostate cancer, al , ovarian cancer,
gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, brain cancer,
neuroendocrine cancer, lung cancer, kidney cancer, hematological malignancies,
melanoma and sarcomas. Especially preferably the cancer is selected from the
group ting of breast cancer, al cancer, ovarian cancer, colorectal cancer,
melanoma and lung cancer. More especially ably the cancer is selected from
the group consisting of lung cancer, melanoma, ovarian cancer and colorectal
cancer. In another preferred embodiment, for the case when the resistance predicted
is acquired ance, the cancer is lung cancer or ovarian cancer. In yet another
preferred embodiment, for the case where the resistance predicted is inherent
resistance, the cancer is selected from the group consisting of colorectal cancer, lung
cancer or melanoma.
Samples
The ement of the level of glu-tubulin may be performed in vitro, on a
sample of ical tissue derived from the subject. The sample may be any
biological material separated from the body such as, for example, normal tissue,
tumour tissue, cell lines, whole blood, serum, plasma, cerebrospinal fluid, lymph fluid,
circulating tumour cells, cell lysate, tissue lysate, urine and aspirates. Preferably the
sample is derived from normal tissue, tumour tissue, or circulating tumour cells. More
preferably the sample is derived from tumour tissue or circulating tumour cells. In one
particularly preferred embodiment the sample is derived from tumour tissue. For
example, the level of glu-tubulin may be measured in a fresh, frozen or formalin
fixed/paraffin embedded tumour tissue .
The sample is pre-obtained from the subject before the sample is subjected
to the method steps involving measuring the level of the ker. The methods for
l of the sample are well known in the art, and it may for example be d
from the subject by biopsy, for e by punch biopsy, core biopsy or aspiration
fine needle biopsy, endoscopic biopsy, or surface biopsy. Blood may be collected by
venipuncture and further processed according to standard ques. Circulating
tumour cells may also be obtained from blood based on, for example, size (e.g. ISET
- Isolation by Size of Epithelial Tumour cells) or immunomagnetic cell enrichment.
(e.g. Cellsearch®, Veridex, Raritan, NJ)
Sample comparison
The t may be human or animal. ably the subject is human.
The biomarker glu-tubulin is measured ex vivo in a sample or samples taken
from the human or animal body, preferably taken from the human body. The sample
or samples are pre-obtained from the human or animal body, ably pre-obtained
from the human body before the sample is subjected to the method steps involving
measuring the level of the biomarker.
A biomarker is in general a substance that is used as an indicator of a
biological response, ably as an indicator of the susceptibility to a given
treatment, which in the present application is treatment with a compound of general
formula I or a pharmaceutically acceptable derivative thereof.
In a particularly preferred ment, higher glu-tubulin levels in the
sample relative to a standard value or set of rd values predicts resistance.
As used herein, an se or relatively high or high or higher levels relative
to a standard level or set of standard levels means the amount or concentration of
the biomarker in a sample is detectably greater in the sample relative to the standard
level or set of standard levels. This encompasses at least an increase of, or higher
level of, about 1% ve to the standard, preferably at least an increase of about
% relative to the standard. More preferably it is an increase of, or higher level of, at
least about 10% relative to the standard. More ularly preferably it is an increase
of, or higher level of, at least about 20% relative to the standard. For example, such
an increase of, or higher level of, may include, but is not limited to, at least about 1%,
about 10%, about 20%, about 30%, about 50%, about 70%, about 80%, about 100%,
about 150% or about 200% or more relative to the standard.
Preferably, higher glu-tubulin levels in a sample or samples
i) relative to a standard value or set of standard values from subjects with
the same tumour histotype; or
ii) taken after treatment initiation and compared to a sample or samples
taken from the same subject before treatment initiation; or
iii) ve to a rd value or set of standard values from normal cells or
are predictive of resistance.
The measuring of a level of glu-tubulin is performed ex-vivo in a sample preobtained
from the subject. Further preferably the response which is to be predicted is
resistance.
More preferably, higher glu-tubulin levels in a sample or samples
i) relative to a rd value or set of standard values from subjects with
the same tumour histotype; or
ii) taken after treatment initiation and compared to a sample or samples
taken from the same t before treatment initiation;
are predictive of resistance.
Especially preferably, higher glu-tubulin levels in a sample or samples
ve to a rd value or set of standard values from subjects with the same
tumour histotype are predictive of ance.
In one preferred embodiment, for the case i) where the measurement is
compared in a sample or samples relative to a standard value or set of standard
values from samples from subjects with the same tumour histotype as the sample to
which it is to be compared, the standard value or set of standard values are
established from samples from a population of subjects with that cancer type. The
samples from these standard subjects may for example be derived from the tumour
tissue, circulating tumour cells or blood, as long as the origin of the sample is
consistent between the standard and the sample to be compared.
In r preferred embodiment, for the case ii) where the measurement is
compared in a sample or s taken after ent initiation and compared to a
sample or samples taken from the same subject before treatment initiation, it is
measured preferably to predict acquired resistance. The samples are ed to
cells or tissue from the same biological origin. The prediction of ed ance
would then indicate that the treatment with the compound should be discontinued.
The biomarker is thus used to monitor whether further treatment with the compound
is likely to give the required response (e.g. reduction of abnormal cells), or whether
the cells have become non-responsive or resistant to such treatment.
In yet another preferred embodiment, for the case iii) where the
ement is compared in a sample or samples ve to a standard value or set
of standard values from normal cells or tissue, the standard value or set of standard
values may be established from a sample of normal (e.g. non-tumourous) cells or
tissue or body fluid. Such data may be gathered from a population of subjects in
order to develop the standard value or set of standard values.
The standard value or set of standard values are established ex-vivo from
pre-obtained samples which may be from cell lines, or preferably biological material
from at least one subject and more preferably from an average of subjects (e.g., n=2
to 1000 or more). The standard value or set of standard values may then be
correlated with the response data of the same cell lines, or same subjects, to
treatment with a compound of general formula I or a pharmaceutically able
derivative thereof. From this correlation a comparator , for example in the
form of a relative scale or scoring system, optionally including cut-off or threshold
values, can be established which indicates the levels of biomarker associated with a
spectrum of response levels to the compound of formula I or a pharmaceutically
acceptable derivative thereof. The spectrum of response levels may comprise
relative sensitivity to the therapeutic activity of the compound, (e.g. high sensitivity to
low sensitivity), as well as resistance to the therapeutic activity. In a preferred
ment this comparator module ses a f value or set of values which
predicts resistance to treatment.
For example, if an immunohistochemical method is used to measure the
level of glu-tubulin in a , standard values may be in the form of a scoring
system. Such a system might take into account the percentage of cells in which
staining for glu-tubulin is present. The system may also take into account the relative
intensity of staining in the individual cells. The standard values or set of standard
values of the level of glu-tubulin may then be correlated with data indicating the
response, especially resistance, of the subject or tissue or cell line to the eutic
activity of a compound of formula I or a pharmaceutically acceptable derivative
f. Such data may then form part of a comparator module.
Response is the on of the cell lines, or preferably of the subject, or
more preferably of the disease in a subject, to the eutic activity of a compound
of general formula I or a ceutically acceptable derivative thereof. The
spectrum of response levels may comprise relative sensitivity to the eutic
activity of the compound, (e.g. high sensitivity to low ivity), as well as resistance
to the therapeutic activity. The se data may for example be monitored in terms
of: objective response rates, time to disease progression, progression free survival,
and overall survival.
The response of a cancerous e may be evaluated by using criteria
well known to a person in the field of cancer treatment, for example but not restricted
Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines, Source:
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J,
Arbuck S,
Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D,
Verweij J. New response evaluation criteria in solid tumours: revised RECIST
guideline (version 1.1). Eur J Cancer.2009; -47;
RANO Criteria for High-Grade Gliomas, Source: Wen PY, Macdonald DR, Reardon
DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR,
Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn
KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment
criteria for high-grade gliomas: response assessment in neuro-oncology working
group. J Clin Oncol.
8(11):1963-72;
CA-125 Rustin Criteria for Ovarian Cancer Response,
Source: Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A,
Eisenhauer E, Sagae S,
Greven K, e I, Cervantes A, Vermorken J. Re: New guidelines to evaluate the
response to
treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004; 96(6):487-8;
PSA Working Group 2 Criteria for Prostate Cancer Response,
Source: Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA,
Eisenberger MA, Higano C,
Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ,
Beer TM, Wilding
G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Design and
end points of clinical trials for patients with progressive te cancer and castrate
levels of testosterone: recommendations of the Prostate Cancer Clinical Trials
Working Group. J Clin Oncol.
2008;26(7):1148-59.
Resistance is associated with there not being an observable and/or
measurable reduction in, or absence of, one or more of the following: reduction in the
number of abnormal cells, preferably cancerous cells; or absence of the abnormal
cells, preferably cancerous cells; for ous diseases: reduction in tumour size;
inhibition (i.e., slowed to some extent and preferably stopped) of r tumour
; reduction in the levels of tumour markers such as PSA and CA-125, inhibition
(i.e., slowed to some extent and ably stopped) of cancer cell infiltration into
other organs (including the spread of cancer into soft tissue and bone); inhibition (i.e.,
slowed to some extent and ably stopped) of tumour asis; alleviation of
one or more of the symptoms associated with the specific cancer; and reduced
morbidity and mortality.
In a preferred embodiment resistance means there is no observable and/or
measurable ion in, or absence of, one or more of the following ia:
reduction in tumour size; inhibition of further tumour growth, inhibition of cancer cell
infiltration into other organs; and inhibition of tumour metastasis.
In a more preferred embodiment resistance refers to one or more of the
following criteria: no reduction in tumour size; no inhibition of further tumour growth,
no inhibition of cancer cell infiltration into other organs; and no inhibition of tumour
metastasis.
ement of the aforementioned ance criteria is according to clinical
guidelines well known to a person in the field of cancer treatment, such as those
listed above for measuring the response of a cancerous disease.
Response may also be established in vitro by assessing cell proliferation
and/or cell death. For example, effects on cell death or proliferation may be assessed
in vitro by one or more of the following well established assays: A) Nuclear staining
with Hoechst 33342 dye providing information about nuclear morphology and DNA
fragmentation which are rks of apoptosis. B) AnnexinV binding assay which
reflects the phosphatidylserine content of the outer lipid bilayer of the plasma
membrane. This event is considered an early hallmark of sis. C) TUNEL assay
(Terminal deoxynucleotidyl transferase mediated dUTP Nick End Labeling assay), a
scence method for evaluating cells undergoing apoptosis or necrosis by
measuring DNA fragmentation by labeling the terminal end of nucleic acids. D) MTS
eration assay measuring the lic activity of cells. Viable cells are
metabolically active whereas cells with a mised respiratory chain show a
reduced ty in this test. E) Crystal violet staining assay, where effects on cell
number are monitored through direct staining of cellular components. F) Proliferation
assay monitoring DNA synthesis through incorporation of bromodeoxyuridine (BrdU).
Inhibitory effects on /proliferation can be directly determined. G) YO-PRO
assay which involves a membrane impermeable, fluorescent, monomeric cyanine,
c acid stain, which permits analysis of dying (e.g. apoptotic) cells without
interfering with cell viability. Overall effects on cell number can also be analysed after
cell permeabilisation. H) Propidium iodide staining for cell cycle distribution which
shows alterations in distribution among the different phases of the cell cycle. Cell
cycle arresting points can be determined. I) Anchorage-independent growth assays,
such as colony outgrowth assays which assess the ability of single cell suspensions
to grow into colonies in soft agar.
In a preferred embodiment relating to determination of resistance in vitro,
resistance means there is no decrease in the proliferation rate of abnormal cells
and/or reduction in the number of abnormal cells. More preferably resistance means
there is no decrease in the proliferation rate of cancerous cells and/or no reduction in
the number of cancerous cells. The ion in the number of abnormal, preferably
cancerous, cells may occur through a variety of programmed and non-programmed
cell death mechanisms. Apoptosis, caspase-independent programmed cell death and
autophagic cell death are examples of programmed cell death. r the cell
death criteria involved in embodiments of the invention are not to be taken as limited
to any one cell death mechanism.
Glu-tubulin
Preferred examples of the protein ce of alpha tubulin (human alpha
tubulin) are listed in SEQ. ID No. 1-4, Figures 11-14. Alpha tubulin is a sor of
bulin. As described previously, the glu-tubulin itself has the C-terminal tyrosine
removed. The term bulin also encompasses homologues, mutant forms, allelic
ts, isoforms, splice variants and equivalents of the sequences ented by
SEQ ID NO 1-4, with the proviso that a glutamate is the final amino acid at the C-
terminal. More preferably it encompasses sequences having at least about 75%
identity, especially preferably at least about 85% identity, particularly ably at
least about 95% identity, and more particularly ably about 99% identity to said
sequences, with in each case the proviso that a glutamate is the final amino acid at
the C-terminal.
Level of glu-tubulin
The level of bulin may be assayed in the sample by protein analysis
techniques well known to a skilled person. Examples of methods known in the art
which are suitable to measure the level of glu-tubulin at the protein level include, but
are not limited to, i) immunohistochemistry (IHC) analysis, ii) western blotting iii)
immunoprecipitation iv) enzyme linked immunosorbant assay (ELISA) v)
radioimmunoassy vi) Fluorescence ted cell sorting (FACS) vii) mass
spectrometry, including matrix assisted laser tion/ionisation (MALDI, e.g.
MALDI-TOF) and electrospray ionisation mass-spectrometry (ESI—MS).
The antibodies involved in some of the above methods may be monoclonal
or polyclonal antibodies, antibody fragments, and/or various types of synthetic
antibodies, including ic dies. The antibody may be labelled to enable it
to be detected or capable of ion following reaction with one or more further
s, for example using a secondary dy that is labelled or capable of
producing a detectable result. Antibodies specific to the glu-tubulin form of alpha
tubulin are available commercially from Milipore or can be prepared via conventional
antibody generation methods well known to a skilled person.
Preferred methods of protein analysis are ELISA, mass spectrometry
techniques, immunohistochemistry and western blotting, more ably western
blotting and immunohistochemistry. In western blotting, also known as
immunoblotting, ed antibodies may be used to assess levels of protein, where
the intensity of the signal from the detectable label corresponds to the amount of
protein, and can be quantified for example by ometry.
Immunohistochemistry again uses labelled antibodies to detect the ce
and relative amount of the biomarker. It can be used to assess the percentage of
cells for which the biomarker is present. It can also be used to assess the localisation
or relative amount of the biomarker in individual cells, the latter is seen as a function
of the intensity of staining.
ELISA stands for enzyme linked immunosorbant assay, since it uses an
enzyme linked to an antibody or antigen for the detection of a specific protein. ELISA
is lly performed as follows (although other variations in methodology exist): a
solid ate such as a 96 well plate is coated with a primary antibody, which
recognises the biomarker. The bound biomarker is then recognised by a secondary
antibody specific for the biomarker. This may be directly joined to an enzyme or a
third anti-immunoglobulin antibody may be used which is joined to an enzyme. A
substrate is added and the enzyme catalyses a reaction, yielding a specific colour.
By measuring the optical density of this colour, the presence and amount of the
biomarker can be determined.
Uses of biomarker
The biomarker may be used to t inherent resistance of the disease in a
subject to the compound of general formula I or a pharmaceutically acceptable
derivative thereof as defined above.
The biomarker may be used to predict acquired resistance of the disease in
a subject to the compound of general formula I or a pharmaceutically acceptable
derivative thereof as defined above.
The biomarker may be used to select subjects suffering or predisposed to
suffering from a disease, preferably cancer, for treatment with a nd of general
formula I or a ceutically acceptable derivative thereof as d above. The
levels of such a biomarker may be used to identify subjects likely to respond or to not
respond or to continue to respond or to not continue to respond to treatment with
such agents. Stratification of subjects may be made in order to avoid unnecessary
treatment regimes. In particular the biomarker may be used to fy subjects from
whom a sample or samples do not display a higher level of bulin, relative to a
standard level or set of standard levels, whereupon such ts may then be
selected for treatment with the compound of formula I or a pharmaceutically
acceptable derivative thereof as d above.
The biomarker may also be used to assist in the determination of treatment
regimes, regarding amounts and schedules of dosing. onally, the biomarker
may be used to assist in the selection of a combination of drugs to be given to a
subject, including a compound or nds of general formula I or a
pharmaceutically acceptable derivative thereof, and another chemotherapeutic
(cytotoxic) agent or . Furthermore, the biomarker may be used to assist in the
determination of therapy gies in a subject including whether a compound of
general formula I or a pharmaceutically acceptable derivative thereof is to be
stered in combination with ed therapy, endocrine therapy, radiotherapy,
immunotherapy or surgical intervention, or a combination of these.
Glu-tubulin may also be used in combination with other biomarkers to predict
the response to a nd of general formula I or a pharmaceutically acceptable
tive thereof and to determine treatment regimes. It may furthermore be used in
combination with chemo-sensitivity testing to predict resistance and to determine
treatment regimes. Chemo-sensitivity testing involves directly applying a compound
of general formula I to cells taken from the subject, for example from a subject with
haematological malignancies or accessible solid tumours, for example breast, head
and neck cancers or melanomas, to determine the response of the cells to the
compound.
Method of treatment
Also described is a method of ent and glu-tubulin for use in a method
of treatment, wherein the level of bulin is first ished relative to a standard
level or set of standard levels or pre-treatment initiation levels and then a compound
of general formula I or a ceutically able derivative thereof as defined
above, is stered if the level of glu-tubulin in said sample is not higher than a
standard value or set of standard values or has not increased relative to pre-
treatment initiation levels respectively. The compound of formula I or a
pharmaceutically acceptable derivative thereof may be administered in a
pharmaceutical composition, as is well known to a person skilled in the art. Suitable
compositions and dosages are for example sed in A1 pages
-39, which are specifically incorporated by reference herein. Compositions for
enteral administration, such as nasal, buccal, rectal or, especially, oral
administration, and for parenteral administration, such as intravenous, intramuscular
or subcutaneous administration, to warm-blooded animals, especially humans, are
especially preferred. More particularly, compositions for intravenous administration
are preferred.
The compositions comprise the active ingredient and a pharmaceutically
acceptable carrier. An example of a composition includes, but is not limited to, the
following: 5000 soft gelatin capsules, each comprising as active ingredient 0.05 g of
one of the nds of general a (I), are prepared as follows: 250 g
pulverized active ingredient is suspended in 2 liter Lauroglykol (propylene glycol
laurate, Gattefossé S.A., Saint Priest, France) and ground in a wet pulverizer to
produce a particle size of about 1 to 3 µm. 0.419 g portions of the mixture are then
introduced into soft gelatin capsules using a capsule-filling machine.
Also bed is a method of treating a neoplastic or autoimmune disease,
preferably cancer, by first decreasing the level of glu-tubulin in a subject that has a
sample with a higher level of glu-tubulin compared to a standard level or set of
standard levels or pre-treatment initiation , then treating the subject with a
nd of general a I or a ceutically acceptable derivative as
defined above. The level of glu-tubulin may be decreased by direct or indirect
chemical or genetic means. Examples of such methods are treatment with a drug
that results in reduced glu-tubulin expression, ed delivery of viral, plasmid or
e constructs, or antibody or siRNA or antisense to downregulate the level of
bulin. For example siRNA may be used to reduce the level of TTCP or delivery
of a plasmid may be used to increase the expression of TTL, and thereby reduce the
level of bulin in the cell. The subject may then be treated with a compound of
general formula I or a pharmaceutically acceptable derivative thereof.
A compound of general formula I or a pharmaceutically acceptable derivative
thereof can be administered alone or in combination with one or more other
eutic agents. le combination therapy may take the form of fixed
combinations, or the administration of a compound as described herein and one or
more other therapeutic agents which are staggered or given independently of one
r, or the combined administration of fixed combinations and one or more other
therapeutic agents.
A compound of general formula I or a pharmaceutically acceptable
derivative thereof can, besides or in addition, be administered especially for tumour
therapy in combination with herapy (cytotoxic therapy), targeted therapy,
endocrine therapy, radiotherapy, immunotherapy, surgical intervention, or a
combination of these. Long-term therapy is equally possible as is adjuvant therapy in
the context of other treatment strategies, as described above. Other possible
treatments are therapy to maintain the patient's status after tumour regression, or
even preventive therapy, for example in patients at risk.
Kit and device
One embodiment relates to a kit and another to a device for predicting the
response, preferably of a disease in a subject, to a compound of general formula I or
a ceutically acceptable derivative thereof as defined above, comprising
reagents necessary for measuring the level of bulin in a sample. Preferably, the
reagents comprise a e t comprising a detector for glu-tubulin and a
detector reagent.
The kit and device may also preferably comprise a comparator module
which comprises a standard value or set of standard values to which the level of glutubulin
in the sample is compared. In a preferred embodiment, the comparator
module is included in ctions for use of the kit. In another preferred embodiment
the comparator module is in the form of a display device, for example a strip of colour
or cally coded al which is designed to be placed next to the t of
the sample measurement to indicate resistance levels. The rd value or set of
standard values may be determined as bed above.
The reagents are ably antibodies or antibody fragments which
selectively bind to glu-tubulin. These may for example be in the form of one specific
primary antibody which binds to glu-tubulin and a secondary antibody which binds to
the primary antibody, and which is itself labelled for detection. Alternatively, the
primary antibody may also be labelled for direct detection. The kits or devices may
optionally also contain a wash solution(s) that selectively allows retention of the
bound biomarker to the capture reagent as compared with other biomarkers after
g. Such kits can then be used in ELISA, western blotting, flow cytometry,
immunohistochemistry or other immunochemical methods to detect the level of the
biomarker.
More preferably the kit comprises a compound of general formula I, or a
pharmaceutically acceptable derivative thereof as defined above. This compound
may then be administered to the subject, in accordance with the level of the
ker in the sample from the subject, as measured by the reagents comprised in
the kit. Therefore the kit according to the invention may be used in the method of
treatment described herein, as defined above. In an especially preferred embodiment
the kit comprises a compound of the ing formula or a pharmaceutically
acceptable salt f
N N
N N O
In a particularly preferred embodiment of the kit the pharmaceutically
acceptable salt is a dihydrochloride salt. Another embodiment relates to the use of
such a kit as described above.
rmore the device may comprise imaging s or measurement
devices (for example, but not restricted to, measurement of fluorescence) which
further process the measured signals and transfer them into a scale in a comparator
module.
In the present specification the words “comprise” or ises” or
“comprising” are to be understood as to imply the inclusion of a stated item or group
of items, but not the exclusion of any other item or group of items.
Experimental methodology
Immunofluorescent staining of cultured cells
A549 human non-small cell lung cancer (NSCLC, ATCC reference number
CCL-185) cells, HeLa cervical cancer cells (ATCC reference number CCL-2) and
SKBR3 breast carcinoma cells (ATCC reference number HTB-30) were seeded at
densities of 50% on round microscope coverslips and ed for 24 hours in RPMI-
1640 containing 10 % FCS (also referred to as FBS) at 37°C, 5% CO2. Compounds
to be tested were dissolved in DMSO. The cell culture medium was replaced with
medium ning the diluted compound(s) (paclitaxel, vinblastine, colchicine and
nocodazole were purchased from Sigma-Aldrich) or e. After treatment for the
times indicated in the Brief Description of the Figures, lips were washed and
cells were fixed in methanol/acetone (1:1) for 5 minutes at room temperature and
subsequently incubated in blocking buffer (0.5% BSA and 0.1% TX-100 in PBS) for
s at room temperature. Specimens were then ted with anti-alpha-
tubulin (Sigma, 1:2000) for 1 hour at room temperature in blocking buffer. After
several washing steps cells were ted with AlexaFluor-488 goat-anti-mouse IgG
(Molecular Probes, 1:3000) for 1 hour at room temperature followed by several
washing steps with blocking buffer. Specimens were then mounted with ProLong
Gold antifade (Molecular Probes, sealed with nail polish and examined with a Leica
immunofluorescence microscope. Images were captured with a cooled mera
and processed by ImageJ software.
Colony Outgrowth Assay:
Single cell suspensions of patient-derived tumour xenografts (maintained in
nude mice) were ed. For colony outgrowth assays, cells were plated in soft
agar in 24-well plates according to the assay introduced by Hamburger & Salmon
(Primary bioassay of human tumour stem cells, Science , 1977,197:461-463). 2x104-
6x10 4 cells in 0.2 mL medium containing 0.4% agar were plated out on a bottom
layer of 0.75% agar. Test compounds were applied in 0.2 mL culture medium. Every
24-well plate ned untreated ls and samples in triplicates. Cultures were
incubated at 37°C and 7.5% CO2 for 5 - 28 days. 24 hours prior to analysis, vital
colonies were d with a solution of metabolisable tetrazolium salt (Alley MC et
al, Life Sci. 1982, 31:3071-3078) and were counted with an automatic image analysis
system (Omnicon 3600, Biosys GmbH).
ve drug effects were expressed by the ratio of the mean number of
colonies in the treated wells and the control wells. IC70 -values were determined by
plotting compound concentrations versus relative colony counts.
Generation and Crystal Violet Assay of BAL27862-Resistant Cell Lines
BAL27862-resistant sublines of human non-small cell lung cancer (H460
ATCC reference HTB-177; A549 ATCC reference CCL-185), ovarian cancer (SKOV3
ATCC reference HTB-77) lines were ted by long-term selection in complete
cell culture medium (RPMI-1640 ning 10% FCS; Sigma-Aldrich) by stepwise
increasing concentrations of BAL27862. Dependent on the cell line, the selection
process was carried out for 8-12 months in order to achieve resistance factors (ratio
of IC50 of resistant cell line and appropriate wild-type cell line) between 3 and 11.6.
The resistant sublines were expanded at the highest tolerated 62
concentration and subsequently frozen and stored in liquid nitrogen.
Cells were seeded in 96 well plates at the following densities: A549: 2000,
H460: 1000, SKOV3: 2000 and, after 24 hours incubation, were incubated for 72
hours with DMSO, BAL27862, colchicine, nocodazole, paclitaxel or vinblastine
diluted in te medium (final concentration DMSO max. 0.5 %). After medium
was d, cells were fixed and stained by adding 50 µl Crystal Violet Staining
(0.2 % Crystal Violet in 50 % Methanol) per well. Plates were incubated for 1 hour at
room temperature. Subsequently the stain was decanted and plates were washed 4
times with double-distilled water. Plates were air-dried for several hours. Stain was
dissolved by adding 100 µl buffer (0.1 M Tris pH 7.5, 0.2 % SDS, 20 % Ethanol) per
well and shaking the . Absorbance at 590 nm was measured using a
SpectraMax M2e plate reader (Molecular s). Anti-proliferative IC50 values
were calculated from concentration response curves using ad Prism
software. Resistance factors were calculated as a ratio of 62 IC50 in the
resistant line variant versus the IC50 in the parental line.
Protein Extraction
Tumour extraction: Tumours were extracted in ice-cold lysis buffer
containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 25 mM β-glycerophosphate,
25 mM NaF, 5 mM EGTA, 1 mM EDTA, 0.1% NP40, 15 mM pyrophosphate, 2 mM
sodium orthovanadate, 10 mM sodium molybdate, leupeptin (10 µg/mL), aprotinin
(10 µg/mL) and 1 mM phenylmethylsulphonyl fluoride (PMSF)(1 mL extraction
volume per 45 mg tumour). After homogenisation by on, lysates were adjusted
to 1% NP40 and incubated on ice for 20 min. Lysates were clarified by centrifugation
and frozen at -80°C.
Tumour cell line extraction: Cells were washed with ice-cold PBS containing
1 mM PMSF and with ice-cold lysis buffer (see above) without NP40. Cells were
extracted in the same lysis buffer containing 1% NP40. After homogenisation, lysates
were clarified by centrifugation and frozen at -80°C.
Immunoblotting/Western Blotting
Immunoblotting was performed using 20 µg of total protein per lane. Total
n concentration was ined with the BCA Protein Assay (Pierce). Protein
was separated on a 10% SDS-gel and transferred to a PVDF membrane using
Semidry Blotting (90 min, 50 mA/gel). The primary dies used for
immunoblotting were as follows:
Glu-tubulin antibody (available from Milipore, reference number AB3201),
rabbit polyclonal, dilution 1:1000, buffer conditions: 3% BSA in PBS/0.1% Tween
Actin antibody (available from Chemicon, nce number MAB1501),
mouse monoclonal, dilution 1:5000, buffer conditions: 3% BSA in PBS/0.1% Tween
The secondary antibodies used for immunoblotting were peroxidase-
conjugated goat anti-rabbit or goat anti-mouse (available from Jackson
ImmunoResearch Laboratories INC: reference number 111144 JIR and 115-
035-146 JIR), dilution , buffer conditions: 0.5% milk in PBS/0,1% Tween.
Labelled bands were revealed using a t Stella 3200 High Performance
Imaging System.
Immunohistochemistry
Fixation of patient-derived tumour xenografts (maintained in nude mice) was
performed in 10 % neutral-buffered in containing 4 % formaldehyde for 20 – 28
hours at room ature. Fixed specimens were kept in a on of 70 % ethanol
for a maximum of one week prior to dehydration and paraffin embedding according to
a standard procedure, using the conditions listed below:
Sequential Treatment time (hours)
70% EtOH 1
80% EtOH 2
99% EtOH 1
100% Isopropanol 0.5
100% Isopropanol 1
Xylol 0.5
Xylol 1
Xylol 1
Paraffin 1
Paraffin 2
Paraffin 2
Paraffin sections of approximately 2 µm were cut and processed by using
the automated immunostainer Benchmark XT® (Roche) g the standard
processing steps. The visualisation of the ic antibody staining was done with
DAB (3,3-diaminobenzidine) as chromogenic substrate at a concentration of 5 mg/ml.
The following primary antibody and processing conditions were used for staining:
Antibody Specification Processing
Anti-Glu-Tubulin, Millipore, #AB3201, Cell conditioning 1 buffer from Roche for
rabbit onal 90 minutes, antibody incubation at 37°C
for 32 minutes at a dilution of 1:50
Detailed examples
Example 1: A ct Mitotic Phenotype Induced by nds of general
a I
Treatment with compound A (BAL27862) or with compound B or compound
C, induced a highly reproducible and distinct microtubule phenotype in all tumour cell
lines tested (shown for compound A in A549, HeLa and SKBR3 cells in Figure 1, and
for compound B and compound C in A549 cells in Figure 2). In dividing cells an
apparent fragmentation of the mitotic spindle occurred, resulting in the formation of
dot-like structures (Figure 1). This ype was shown to be ct from that
observed with conventional microtubule targeting , such as the microtubule
stabiliser paclitaxel and the microtubule destabilisers vinblastine and colchicine
(Figure 3) and nocodazole (Figure 4).
Example 2: BAL27862 Overcomes Microtubule Phenotype Induced by
Conventional Microtubule-targeting Drugs in a Dominant Fashion
In order to show the uniqueness of its activity on microtubules, BAL27862
was tested in combination with vinblastine, colchicine and paclitaxel e 5) and
nocodazole (Figure 6) using A549 cells. Treatment with vinblastine, colchicine,
paclitaxel or nocodazole alone induced the mitotic microtubule phenotypes
teristic of these agents. However, combination treatment with BAL27862 for
the last 4 hours resulted in disruption of the ubule structures; creating a
phenotype consistent with treatment of BAL27862 alone, despite the continued
presence of vinblastine, colchicine, paclitaxel or nocodazole. In contrast, ng first
with BAL27862 and subsequently for 4 hours in combination with vinblastine,
colchicine, paclitaxel or nocodazole had no impact on the ed microtubule
phenotype that was consistent with treatment with BAL27862.
These data demonstrate that compounds of formula I affect microtubule
biology consistently, but in a different manner than conventional microtubule
ing .
Detailed Examples according to the invention and/or disclosure
Example 3: Association of high glu-tubulin expression levels with patientderived
tumour cells resistant to BAL27862 treatment.
Based on colony wth assays, using tumour cells derived from 6
patient-derived tumours maintained as xenografts in mice, BAL27862-sensitive or
relatively resistant tumour cells were identified from melanoma and colorectal and
lung cancer (see Table 1). Concentrations at which 70% growth inhibition was
observed versus controls (IC70 ) are shown in Table 1. In this table, BAL27862-
ive tumour cells have IC70 values in the low nanomolar range, while BAL27862-
resistant tumour cells are defined by IC70 values >600 nanomolar. Paclitaxel and
stine data, using the same ex vivo assay, was available for 5 of the 6 tumour
models. Of these 5 , all were resistant to treatment with paclitaxel, while 4 of 5
of these tumours were sensitive to treatment with vinblastine.
Table 1
Cancer type name Response IC70 Response to Response to
to BAL27862 paclitaxel vinblastine
BAL27862 [microM]
Colorectal CXF 1103 Sensitive 0.022 Resistant Resistant
cancer CXF 243 Resistant 0.696 Resistant Sensitive
Lung LXFE 211 Sensitive 0.021 Resistant Sensitive
cancer LXFE 397 Resistant > 3.5 Not known Not known
Melanoma MEXF 1341 Sensitive 0.025 Resistant ive
MEXF 276 Resistant > 3.5 Resistant Sensitive
Immunoblotting analysis was performed in order to measure glu-tubulin
levels in the same tumours ined as xenografts, using the Milipore dy
e 7). The actin levels were included on the blot as a loading control.
Analysis of glu-tubulin levels indicated that glu-tubulin expression varied
dramatically across all the tumours measured (Figure 7).
Based on the colony outgrowth assay and the same IC70 criteria, there was
no association between paclitaxel or vinblastine resistance and high glu-tubulin
levels. This is t since, for example, for the melanoma tumour type, both
models were resistant to paclitaxel and yet for MEXF 1341 the glu-tubulin levels were
clearly lower than in MEXF 276. The same lack of association was true for the vinca
alkaloid, stine in the melanoma model, since both these tumours were sensitive
to stine. Thus glu-tubulin levels were shown to be unsuitable as a reliable
biomarker of resistance to the conventional microtubule agents paclitaxel and
vinblastine in patient-derived tumour models.
Surprisingly, in contrast, when the BAL27862 resistance data is compared
with the glu-tubulin level, glu-tubulin is shown to be higher only in the resistant
s and not the sensitive tumours derived from the same tumour histotype.
Increased levels were therefore consistently indicative of resistance to BAL27862.
Thus glu-tubulin levels were shown to be a biomarker of ance for the compound
described herein, BAL27862.
e 4: Immunohistochemical analysis of colorectal tumour xenografts
Immunohistocehmical analysis was performed on the colorectal tumour
xenografts (Figure 8), ing a high level of glu-tubulin in the tumour model CXF
243. Again a clear ation was seen between high levels of glu-tubulin and
resistance to BAL27862 (tumour model CXF 243 was BAL27862-resistant, while
tumour model CXF 1103 was BAL27862-sensitive; as d by the colony
outgrowth assay). Thus glu-tubulin levels were again shown to be a biomarker of
resistance for the compound described herein, BAL27862.
Example 5: Higher glu-tubulin expression is observed in tumour lines
selected for resistance to a compound of general formula I
In vitro selection for resistance to BAL27862 resulted in the generation of
three relatively resistant tumour cell lines, with the following resistance factors versus
parental lines (based on IC50 determinations using the l Violet assay): A549
(3.0 fold); SKOV3 resistant 1 (7.6 fold); SKOV3 resistant 2 (11.6 fold); H460 (5.3
Table 2).
Table 2:
Resistance factors (ratio of IC50 BAL27862-resistant cell line
Treatment variant and IC50 al cell line)
compound SKOV3 SKOV3
A549 H460
resistant 1 resistant 2
BAL27862 3.0 5.3 7.6 11.6
Colchicine 0.9 1.6 2.0 2.8
zole 1.6 1.3 3.6 3.9
Vinblastine 2.3 4.6 15.7 17.8
Paclitaxel 0.06 0.3 0.4 0.5
In general these BAL27862-resistant cells exhibited a different level of response to
other microtubule destabilising agents, such as cine, nocodazole and
vinblastine, as compared to BAL27862; and indeed increased sensitivity to the
microtubule stabiliser paclitaxel was observed in all lines (Table 2).
Extraction and immunoblot analysis of these lines to measure the glu-tubulin
levels, followed by comparison to BAL27862 resistance data, again shows that glutubulin
is higher in the ant lines, as compared to the parental lines (Figure 9).
This was maintained hout resistance development in the SKOV3 cells (Figure
). These data show the association of increased glu-tubulin expression levels with
acquired resistance to BAL27862.
List of abbreviations
A549 human all cell lung cancer cell line
AnnexinV phosphatidylserine-binding protein
BCA bicinchoninic acid
Bcl-2 B-cell lymphoma 2 protein
BRCA1 breast cancer type 1 susceptibility protein
BrdU bromodeoxyuridine
BSA bovine serum albumin
CA-125 cancer antigen 125
cDNA complementary deoxyribonucleic acid
CREST limited scleroderma syndrome
CO2 carbon dioxide
CXF 243 t-derived colorectal tumour
CXF 1103 t-derived colorectal tumour
DAB 3,3-diaminobenzidine
DMSO dimethylsulphoxide
DNA deoxyribonucleic acid
dUTP 2´-Deoxyuridine 5´-Triphosphate
ELISA -linked immunosorbent assay
ErbB-2 human epidermal growth factor or 2
ESI-MS electrospray ionisation mass-spectrometry
EtOH Ethanol
FACS fluorescence activated cell scan/sorting
FCS/FBS foetal calf / foetal bovine serum
G2/M transition from G2 to the c phase in the cell cycle
HeLa human squamous cell cancer cell line
HEPES 4-(2-Hydroxyethyl)piperazineethanesulphonic acid
Hoe33342 2'-(4'-Ethoxyphenyl)(4-methylpiperazinyl)-2,5'-bis-1H-
benzimidazole trihydrochloride trihydrate
H460 human non-small cell lung cancer cell line
IgG immunoglobulin G
IHC Immunohistochemistry
LXFE 211 Patient-derived lung tumour
LXFE 397 Patient-derived lung tumour
MALDI matrix-assisted-laser-desorption/ionisation massspectrometry
MALDI-TOF matrix-assisted-laser-desorption/ionisation–time-of-flightmass-spectrometry
MEXF 276 patient-derived melanoma
MEXF 1341 patient-derived melanoma
mRNA messenger ribonucleic acid
MTS 3-(4,5-dimethylthiazolyl)(3-carboxymethoxyphenyl)
(4-sulphophenyl)-2H-tetrazolium
NaCl Sodium chloride
NaF Sodium fluoride
NCBI National Center for Biotechnology Information
NSCLC non-small cell lung cancer
NP40 Nonidet P40
PBS phosphate buffered saline
PCR polymerase chain on
P-gp P-glycoprotein
PMSF phenylmethylsulphonyl fluoride
PSA prostate-specific antigen
PVDF polyvinylidene fluoride
RANO response assessment for high-grade gliomas
RECIST response tion criteria in solid tumours
RNA ribonucleic acid
640 cell culture medium used for culturing transformed and
non-transformed eukaryotic cells and cell lines
SDS sodium dodecyl sulphate
SEQ. ID No. sequence identification number
siRNA small inhibitory ribonucleic acid
SKBR3 human mammary carcinoma cell line
SKOV3 human ovarian carcinoma cell line
TTCP tubulin ne carboxypeptidase
TTL tubulin tyrosine ligase
TUNEL terminal deoxynucleotidyl transferase dUTP nick end
labeling
Tween-20 detergent, Polyoxyethylene sorbitan monolaurate
TX-100 Triton-X100
YO-PRO fluorescent, monomeric cyanine, nucleic acid stain
The term ‘comprising’ as used in this specification and claims means ‘consisting at
least in part of’. When interpreting statements in this specification and claims which
includes the ‘comprising’, other features besides the features ed by this term in
each statement can also be present. Related terms such as ‘comprise’ and
‘comprised’ are to be interpreted in similar .
In this specification where reference has been made to patent specifications, other
al nts, or other sources of information, this is generally for the purpose
of providing a t for discussing the features of the invention. Unless specifically
stated otherwise, reference to such external documents is not to be construed as an
admission that such documents, or such sources of information, in any jurisdiction,
are prior art, or form part of the common general knowledge in the art.
Claims (25)
1. Use of glu-tubulin as a biomarker for predicting the response to a compound, wherein the compound is a compound of general formula I R3 R2 N R4 N R5 N N 5 wherein R represents phenyl, l or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, 10 y-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower -lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form er with the nitrogen heterocyclyl, lower alkylcarbonyl, y, lower 15 alkoxycarbonyl, cyano, halogen, and nitro; and wherein two adjacent substituents are methylenedioxy; and wherein nyl is optionally tuted by lower alkoxy, amino or halogen; X represents a group C=Y, wherein Y stands for oxygen or nitrogen substituted by 20 hydroxy or lower alkoxy; R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or cyano-lower alkyl; R2, R3 and R6 represent hydrogen; 25 R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower alkoxy; or R4 and R5 together represent methylenedioxy; and pharmaceutically acceptable salts, solvates, esters and amides of naturally occurring amino acids, small es or pegylated hydroxyl acids, salts of such 5 esters and amides, and polymorphs thereof; or wherein R represents phenyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently 10 selected from alkyl, ower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, y, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, kylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form 15 together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, formyl, cyano, halogen, and nitro; and wherein two adjacent substituents are enedioxy; and wherein pyridinyl is optionally substituted by lower , amino or halogen; 20 X represents oxygen; R1 represents hydrogen, lower alkylcarbonyl, hydroxy-lower alkyl or lower alkyl; R2, R3 and R6 ent hydrogen; 25 R4 and R5, independently of each other, represent hydrogen, lower alkyl or lower alkoxy; or R4 and R5 together represent methylenedioxy; and pharmaceutically acceptable salts, solvates, esters and amides of naturally occurring amino acids, small peptides or pegylated hydroxy acids, salts of 30 such esters and amides, and polymorphs thereof, and wherein the prefix lower denotes a radical having up to and including a m of 7 carbon atoms and, wherein the response is of a disease in a subject and the biomarker glu-tubulin is measured ex vivo in a sample or samples taken from the human or animal body.
2. Use according to claim 1, wherein the sample or samples are taken from the human body. 5 3. Use according to claim 1 or claim 2, wherein in the compound of general formula I R represents phenyl or pyridinyl; wherein phenyl is optionally substituted by one or two substituents independently selected from lower alkyl, lower alkoxy, amino, acetylamino, halogen and nitro; 10 and wherein pyridinyl is optionally tuted by amino or halogen; X represents a group C=O; R1 represents hydrogen or cyano-lower alkyl; 15 R2, R
3, R4, R5 and R6 represent hydrogen; and ceutically acceptable salts, solvates, esters and amides of naturally occurring amino acids, small peptides or pegylated y acids, salts of such esters and amides, and polymorphs f, and wherein the prefix lower s a radical having up to and including a maximum of 7 carbon atoms.
4. Use according to any one of claims 1 to 3, wherein the compound is represented by the following formula N N wherein R, Y and R1 are defined as follows: R Y R1 O CH2CH2CN O H O CH2CH2CN NH N or pharmaceutically acceptable salts, solvates, esters and amides of naturally 5 occurring amino acids, small peptides or pegylated y acids, salts of such esters and amides, and polymorphs thereof.
5. Use according to any one of claims 1 to 4, wherein the compound is N N N N O or pharmaceutically acceptable salts, solvates, esters and amides of naturally ing amino acids, small peptides or pegylated hydroxy acids, salts of such esters and amides, and polymorphs thereof.
6. Use according to any one of claims 1 to 5, wherein the prefix lower 5 denotes a radical having up to and including a maximum of 4 carbon atoms.
7. Use according to any one of claims 1 to 6, wherein an amide of the compound of formula I with glycine, alanine or lysine is used as a pro-drug, the amide being formed from an amino group present within the R group of the compound of general formula I as defined in any one of claims 1 to 5 and the carboxy 10 group of e, alanine or lysine.
8. Use according to any one of claims 1 to 7, wherein the compound is N N N N O 15 or a pharmaceutically acceptable salt thereof.
9. Use according to claim 8, wherein the pharmaceutically acceptable salt is a hloride salt or dihydrochloride salt.
10. Use according to any one of claims 1 to 9, for predicting the resistance of the disease in the t to said compound.
11. Use according to any one of claims 1 to 10, wherein the disease is a stic disease or mune disease.
12. Use according to claim 11, n the disease is cancer.
13. Use according to any one of claims 1 to 11, wherein the disease is 5 selected from the group consisting of breast cancer, prostate cancer, cervical cancer, ovarian cancer gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, brain cancer, neuroendocrine cancer, lung cancer, kidney cancer, logical malignancies, melanoma and sarcomas.
14. Use according to claim 13, wherein the disease is ed from the 10 group consisting of breast cancer, cervical cancer, ovarian cancer, colorectal cancer, lung cancer and melanoma.
15. Use according to claim 14, n the disease is selected from the group consisting of ovarian cancer, colorectal cancer, lung cancer and melanoma.
16. Use according to any one of claims 1 to 15, wherein a higher level of 15 glu-tubulin in the sample from the subject relative to a standard value or set of standard values predicts resistance.
17. Use according to claim 16, wherein higher glu-tubulin levels in a sample or samples i) relative to a standard value or set of standard values from subjects with 20 the same tumour histotype; or ii) taken after treatment initiation and ed to a sample or samples taken from the same subject before treatment tion; or iii) ve to a standard value or set of standard values from normal cells or tissue; are predictive of resistance.
18. Use according to any one of claims 1 to 17, wherein the ker is used to select subjects suffering or predisposed to suffering from a disease for treatment with a nd of general formula I or with a pharmaceutically 5 acceptable salt, solvate, ester or amide of a naturally occurring amino acid, small peptide or pegylated hydroxy acid, or with a salt of such ester or amide or with a polymorph thereof as defined in any one of claims 1 to 9.
19. Use according to claim 18, wherein the disease is cancer.
20. Use according to any one of claims 1 to 19, wherein the sample is 10 derived from normal tissue, tumour tissue, or circulating tumour cells.
21. Use according to claim 20, wherein the sample is derived from tumour tissue.
22. A method for predicting in a t suffering from a cancer the response of that cancer to a compound of general a I or to a pharmaceutically 15 acceptable salt, solvate, ester or amide of a naturally occurring amino acid, small peptide or pegylated hydroxy acid, or to a salt of such ester or amide, or to a polymorph f, as defined in any one of claims 1 to 9, comprising the steps of: a) measuring ex vivo a level of glu-tubulin in a sample pre-obtained from tumour tissue or circulating tumour cells of the subject to obtain a value 20 or values representing this level; and b) comparing the value or values from step a) to a standard value or set of standard values from ts with the same cancer type, wherein a higher glu-tubulin level in the sample relative to the standard value or set of standard values is tive of resistance of the subject's cancer to the 25 compound of formula (I) or to the pharmaceutically acceptable salt, solvate, ester or amide of a naturally occurring amino acid, small peptide or pegylated hydroxy acid, or salt of such ester or amide, or polymorph thereof.
23. Use of a compound of general formula I or of a pharmaceutically acceptable salt, solvate, ester or amide of a naturally ing amino acid, small peptide or pegylated hydroxy acid, or polymorph thereof as defined in any one of 5 claims 1 to 9, for the preparation of a pharmaceutical composition for treating a cancer in a t in need thereof, wherein the subject is selected for treatment with the nd of general formula I or with the salt, solvate, ester or amide of a naturally occurring amino acid, small peptide or pegylated hydroxy acid, salt of such ester or amide, or polymorph thereof as defined in any one of claims 1 to 9, if the 10 level of glu-tubulin, measured ex vivo in a sample taken from the subject, is not higher than a standard value or set of rd values from subjects with the same tumour histotype or from normal cells, tissue or body fluid.
24. A kit when used for predicting the response to a compound of general formula I or a pharmaceutically acceptable salt, solvate, ester or amide of a naturally 15 occurring amino acid, small peptide or pegylated hydroxy acid, salt of such ester or amide, or polymorph thereof, as defined in any one of claims 1 to 9, comprising reagents necessary for measuring a level of glu-tubulin in a sample taken from a subject with a cancer, comprising a compound of the ing formula N N N N O 20 or a pharmaceutically acceptable salt f and further comprising a comparator module which comprises a rd value or set of standard values of a level of glu-tubulin taken from samples of tumour tissue or circulating tumour cells of subjects with a cancer of the same histotype to which the level of bulin in the sample is compared. 5
25. The kit according to claim 24, wherein the reagents comprise a capture reagent comprising a detector for glu-tubulin and a detector reagent.
26. The kit according to claim 25, n the capture reagent is an antibody.
27. The kit according to any one of claims 24 to 26, wherein the 10 pharmaceutically acceptable salt of the compound is the dihydrochloride salt.
28. A use as d in any one claims 1 to 21 or 23, substantially as herein described with reference to any example f.
29. A method as claimed in claim 22, substantially as herein described with 15 reference to any example thereof.
31. A kit as claimed in any one of claims 24 to 27, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11151681 | 2011-01-21 | ||
EP11151681.1 | 2011-01-21 | ||
PCT/EP2012/050814 WO2012098203A1 (en) | 2011-01-21 | 2012-01-19 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ611525A NZ611525A (en) | 2015-06-26 |
NZ611525B2 true NZ611525B2 (en) | 2015-09-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10067120B2 (en) | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | |
US10656162B2 (en) | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | |
US10724072B2 (en) | Use of phospho-Akt as a biomarker of drug response | |
EP2666015B1 (en) | Use of stathmin as a biomarker of drug response to furazanobenzimidazoles | |
AU2012208520A1 (en) | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | |
AU2012208521B9 (en) | Use of stathmin as a biomarker of drug response to furazanobenzimidazoles | |
NZ611525B2 (en) | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | |
NZ613022B2 (en) | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles | |
NZ614718B2 (en) | Use of phospho-akt as a biomarker of drug response | |
NZ611805B2 (en) | Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles |